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I. Background: 
The current clinical practice of factor VIII (FVIII) prophylaxis revolves around 
converting patients with severe hemophilia A, hereafter simply referred to as hemophilia, 
phenotype (defined as plasma factor VIII coagulant activity [FVIII:C] <1 IU dL
-1
) to moderate 
xxi 
hemophilia phenotype (defined as plasma FVIII:C from 1–5 IU dL-1). However, a wide inter-
individual variation in bleeding tendency is observed despite changes in plasma FVIII:C 
(pharmacokinetic [PK] changes). Therefore, monitoring FVIII prophylaxis by global hemostasis 
biomarkers (pharmacodynamic [PD] response) can potentially be beneficial. 
II. Objective: 
To conduct appropriate PK/PD modeling using plasma FVIII:C and global hemostasis 
(platelet function and blood viscoelastic) biomarkers in severe hemophilia. 
III. Methods: 
Nine non-bleeding severe hemophiliacs (plasma FVIII:C <1 IU dL
-1
) with variant 
bleeding tendency (5 frequent bleeders and 4 infrequent bleeders) were infused with a 
recombinant factor FVIII (rFVIII) prophylactic dose (mean = 32.1 international units per 
kilogram [IU kg
-1
]). Blood was collected at baseline and 0.5-, 1-, 2-, 4-, 8-, 12-, 24- and 48-hours 
(h) post-dose for plasma FVIII:C, platelet function (platelet contractile force [PCF], clot elastic 
modulus [CEM] and  force onset time [FOT]) and blood viscoelastic (reaction-time [R], kinetics-
time [K] and maximum amplitude [MA]) biomarkers and activated partial thromboplastin time 
(aPTT). Non-compartmental analysis (NCA) was performed using standard methods. 
Compartmental analysis (CA) and PK/PD modeling were performed by non-linear regression. 
Correlation and analysis of variance (ANOVA) were used to explore the role of clinically 
relevant modifiers of bleeding tendency, as appropriate. ANOVA was used to assess inter-group 
differences in pertinent PK and PD parameters. P value <0.05 significance level was pre-
specified for all statistical tests.  
xxii 
IV. Results: 
Mean (±SD) volume of distribution at steady state (Vss), total clearance (CLtot) and 
terminal half-life (t1/2) from NCA were 40.5 (±11.2) milliliter per kilogram (mL kg
-1
), 2.9 (±1.2) 
milliliter per hour per kilogram (mL h
-1
 kg
-1
) and 11.6 (±6.2) h, respectively. Mean (±SD) Vss 
and CLtot from the one-compartment body model (CA) were 39.6 (±8.9) mL kg
-1
 and 3.1 (±1.3) 
mL h
-1
 kg
-1
, respectively. The mean (±SD) baseline effect (E0) and slope from the PK/PD linear 
modeling were: for aPTT, 48.9 (±4.4) seconds (sec) and -0.025 (±0.009) second deciliter per 
international unit (sec dL IU
-1
), respectively; for PCF, 0.3 (±0.3) kilodynes (kdynes) and 0.008 
(±0.004) kilodynes deciliter per international unit (kdynes dL IU
-1
), respectively; and for CEM, 
0.0 (±0.0) kilodynes per square centimeter (kdynes cm
-2
) and 0.032 (±0.016) kilodynes deciliter 
per international unit per square centimeter (kdynes dL IU
-1
 cm
-2
), respectively. The mean (±SD) 
maximum effect (Emax) and half the maximum effective concentration (EC50) from the PK/PD 
sigmoidal Emax model were: for FOT, 70.1 (±16.9) % reduction and 87.8 (±31.4) IU dL
-1
 for 
FOT, respectively; for R, 74.9 (±26.0) % reduction and 68.5 (±28.4) IU dL
-1
, respectively; and 
for K, 73.2 (±36.4) % reduction and 67.2 (±29.0) IU dL
-1
, respectively. MA was not PK/PD 
modeled due to its low sensitivity. 
V. Conclusions: 
Plasma FVIII:C remained ≥1 IU dL-1 over the prophylactic interval. FOT and R were the 
most sensitive biomarkers at lower plasma FVIII:C. PCF and CEM were more sensitive than K 
and aPTT at lower plasma FVIII:C. MA was the least sensitive biomarker. Correlation and inter-
group differences did not reach statistical significance (small sample size). These results may be 
used to assess risk of bleeding and dose-optimize FVIII prophylaxis in severe hemophilia.
 1 
CHAPTER 1. BACKGROUND 
1.1. HEMOPHILIA A: 
1.1.1. Definition and Epidemiology of Hemophilia A: 
Hemophilia A or classic hemophilia, hereafter simply referred to as hemophilia, is a 
coagulation disorder that is caused by a recessive X-linked deficiency of FVIII.
[1–3]
 The mutant 
X-chromosome is expressed in males and carried in females, making hemophilia a disease of 
males with carrier females.
[1–3]
 In 2009, the prevalence of hemophilia was 115,204 males in 105 
countries.
[4]
 The mean global per capita usage of FVIII, the blood coagulation factor replacement 
therapy used in hemophilia, was 2.02 international units ( IU) in 2009.
[4]
 The total annual global 
FVIII consumption was 7,333,984,513 IU for the same year.
[4]
 Hemophilia is found in all ethnic 
groups worldwide.
[1]
 
1.1.2. Pathophysiology of Hemophilia A: 
Males with hemophilia have the defective allele on the X-chromosome without a 
matching allele on the Y-chromosome while carrier females have only one defective allele.
[1]
 
Sons of a father with hemophilia would be normal if the mother is not a carrier; however, 
daughters would be mandatory carriers (Figure 1.1 ).
[1]
 If the father does not have hemophilia, 
sons and daughters of a carrier mother would have 50% chance of being hemophiliacs and 
carriers, respectively (Figure 1.1).
[1]
 Therefore, there is a skipped generation inheritance pattern 
with hemophilia in which carrier females do not exhibit the disease but can transmit the defective 
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X-chromosome to the next male generation, who exhibit the disease.
[5]
 Sons of a father with 
hemophilia and a carrier mother have 50% chance of being hemophiliac whereas daughters 
would be either hemophiliacs (very rare) or carriers (Figure 1.1).
[1,6]
 
The pathophysiology of hemophilia on the molecular level includes mutation in the FVIII 
gene that encodes FVIII.
[2]
 Several mutations in the FVIII gene have been documented, including 
point mutations, deletions and insertions.
[2]
 The most common mutation in the FVIII gene is 
intron 22 inversion.
[2]
 The intron 22 inversion accounts for about 50% of severe hemophilia 
abnormalities.
[2]
 Another common mutation in the FVIII gene is intron 1 inversion.
[2]
 The intron 
1 inversion accounts for about 5% of severe hemophilia abnormalities.
[2]
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Figure 1.1. Inheritance of Hemophilia 
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1.1.3. Diagnosis of Hemophilia A: 
Hemophilia is suspected due to a recognized family history of coagulation disorders or 
after the occurrence of unusual bleeding.
[1,2]
 The clinical manifestations of hemophilia (Table 
1.1) are typically first detected upon an excessive unusual bleeding.
[7–9]
 Upon an initial diagnosis 
of hemophilia, the diagnosis is confirmed in clinical settings by appropriate laboratory tests 
(Table 1.2).
[1,2,9]
 In hemophilia, laboratory tests indicate a low FVIII plasma level, measured as 
FVIII coagulant activity (FVIII:C) in plasma, and a prolonged activated partial thromboplastin 
time (aPTT); however, prothrombin time (PT), von Willebrand factor (vWF) plasma level and 
platelet count are normal.
[1,2,9]
 Genetic testing for hemophilia is recommended for a more 
confirmatory diagnosis, especially for carrier females.
[1,2]
 Upon successful diagnosis of 
hemophilia with unknown family history, other family members should be screened.
[1]
 
Table 1.1. Clinical Manifestations of Hemophilia
[7–9] 
Signs and Symptoms 
• Ecchymosis, erythema and swelling 
• Hemarthrosis, arthropathy and joints deformity 
• Musculoskeletal hemorrhage and impairment 
• Genitourinary hemorrhage and hematuria 
• Gastrointestinal hemorrhage and melena 
• Intracranial hemorrhage 
• Bleeding after surgeries and dental procedures 
• Limited mobility, nerve palsy and pain 
 
Table 1.2. Laboratory Testing of Hemophilia
[1,2,9]
 
Test Value 
Plasma FVIII:C Low 
aPTT Prolonged 
PT Normal 
vWF plasma level Normal 
Platelet count Normal 
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1.1.4. Classification of Hemophilia A: 
Hemophilia is classified into three phenotypes: severe, moderate and mild (Table 
1.3).
[1,3,10]
 This classification is based on plasma FVIII:C.
[1,3,10]
 Severe hemophilia phenotype is 
defined as plasma FVIII:C <1 international unit per deciliter (IU dL
-1
).
[1,3,10]
 Moderate 
hemophilia phenotype is defined as plasma FVIII:C from 1–5 IU dL-1.[1,3,10] Mild hemophilia 
phenotype is defined as plasma FVIII:C  >5–40 IU dL-1.[1,3,10] The clinical presentations of 
hemophilia phenotypes are assumed to match the measured plasma FVIII:C.
[1,10]
 In case of 
severe FVIII deficiency (plasma FVIII:C <1 IU dL
-1
), severe clinical presentations that include 
spontaneous bleeding in joints and muscles, and bleeding due to injuries, accidents, surgeries and 
dental procedures are observed.
[1,10]
 In case of moderate FVIII deficiency (plasma FVIII:C from 
1–5 IU dL-1), moderate clinical presentations that include bleeding in joints and muscles due to 
insignificant injuries, and bleeding due to accidents, surgeries and dental procedures are 
observed.
[1,10]
 In case of mild FVIII deficiency (plasma FVIII:C  >5–40 IU dL-1), mild clinical 
presentations that include absence of spontaneous bleeding in joints and muscles, and possible 
bleeding due to significant injuries, accidents, surgeries and dental procedures are observed.
[3,10]
 
Table 1.3. Classification of Hemophilia
[1,3,10] 
Phenotype 
Plasma FVIII:C 
(IU dL
-1
) Clinical Presentations 
Severe <1
 • Spontaneous bleeding in joints and muscles; bleeding due 
to injuries,  accidents, surgeries and dental procedures 
Moderate 1–5 • Bleeding in joints and muscles due to insignificant injuries; 
bleeding due to accidents, surgeries and dental procedures 
Mild >5–40 • No spontaneous bleeding in joints and muscles; possible 
bleeding due to significant injuries, accidents, surgeries 
and dental procedures 
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1.1.5. Management of Hemophilia A: 
Hemophilia management necessitates a comprehensive multidisciplinary healthcare.
[11]
 
Hemophilia patients are best treated in a specialized center, usually referred to as hemophilia 
treatment center (HTC), with trained healthcare professionals and appropriate services.
[11]
 
Healthcare professionals involved in an HTC include hematologists, nurses, orthopedic surgeons, 
physical therapists, pharmacists, dentists, psychologists, social workers and genetic 
counselors.
[11]
 Healthcare services required in an HTC includes clinical laboratory, radiology and 
pharmacy.
[11]
 
The primary goal in hemophilia is to prevent or treat bleeding episodes in order to 
prevent or reduce related complications, e.g., joint damage (arthropathy).
[12]
 The main 
pharmacotherapy for bleeding episodes in hemophilia is FVIII replacement therapy.
[12]
 FVIII is a 
parenteral product, and therefore it requires extensive training to learn how to administer FVIII 
at home.
[13]
 Family members may learn how to infuse FVIII for younger children with 
hemophilia.
[13]
 Older children and adults with hemophilia may also learn how to self-infuse 
FVIII.
[13]
 In case of difficult venous access, home nursing support is available.
[13]
 Due to risk of 
transmitting viral infection through FVIII products, routine immunizations, including hepatitis A 
virus (HAV) and hepatitis B virus (HBV), should be provided to hemophiliacs.
[14]
 
An extended use of FVIII therapy is associated with development of FVIII inhibitory 
antibodies.
[12]
 FVIII inhibitory antibodies neutralize the infused FVIII therapy, and therefore 
FVIII therapy becomes ineffective.
[12]
 In 2009, the prevalence of clinically identified FVIII 
inhibitory antibodies in hemophilia was 5,013 (out of 115,204) males.
[4]
 Recombinant FVIII 
(rFVIII) products have a higher risk of developing FVIII inhibitory antibodies compared to 
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plasma-derived FVIII (pdFVIII) products.
[12]
 The pharmacotherapy for bleeding episodes in the 
presence of FVIII inhibitory antibodies requires administration of a hemostatic bypassing agent 
that is able to initiate blood clotting without the presence of FVIII.
[12]
 Current commonly used 
hemostatic bypassing agents include activated prothrombin complex concentrate (aPCC) and 
activated recombinant factor VII (rFVIIa).
[12]
 
The pharmacotherapy for bleeding episodes in hemophilia also includes 1-desamino-8-D-
arginine vasopressin (desmopressin), antifibrinolytics and fibrin sealants.
[12]
 Desmopressin is a 
synthetic analog of vasopressin, the antidiuretic hormone.
[12]
 Desmopressin increases plasma 
FVIII:C as well as plasma level of vWF (FVIII carrier and protector against early degradation by 
plasma proteases).
[12]
 Therefore, desmopressin can be used in mild and moderate bleeding 
episodes of hemophilia.
[12]
 Desmopressin can actually cause two-fold to six-fold elevation in 
plasma FVIII:C.
[12]
 Desmopressin  mechanism of action (MOA) is poorly understood.
[12]
 
However, desmopressin is hypothesized to release FVIII and vWF from their endogenous 
storage sites.
[12]
 Desmopressin is administered intravenously.
[12]
 
Antifibrinolytics, e.g., tranexamic acid and epsilon-aminocaproic acid (EACA), inhibit 
clot lysis. 
[12]
 Therefore, antifibrinolytics are used as an adjunctive therapy in hemophilia 
bleeding episodes.
[12]
 Antifibrinolytics are particularly useful in mucosal surface bleeding and 
oral surgery.
[12]
  Antifibrinolytics are administered topically, orally or intravenously.
[12]
 
Fibrin sealants are a mixture of thrombin and fibrinogen.
[12]
 Thrombin in fibrin sealants 
converts fibrinogen to an insoluble fibrin clot.
[12]
 Therefore, fibrin sealants stop hemophilia 
bleeding episodes in oral and maxillofacial surgery as well as in orthopedic surgery.
[12]
 Fibrin 
sealants are applied topically.
[12]
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Pain, acute and chronic, is common in hemophilia.
[12]
 Acute pain is caused by joint 
bleeding (hemarthrosis).
[12]
 Repeated hemarthrosis may progress to chronic arthropathy that 
causes chronic pain.
[12]
 Therefore, treatment of bleeding is essential for pain management. There 
are no specific guidelines for pain management in hemophilia.
[12]
 Nevertheless, aspirin, a non-
steroidal anti-inflammatory drug (NSAID), should be avoided due to its antiplatelet effect.
[12]
 
Other NSAIDs also have antiplatelet effect.
[12]
 However, NSAIDs are not clinically proven to 
increase the bleeding tendency in hemophilia.
[12]
 Acetaminophen is considered safe but not 
specifically effective.
[12]
 Narcotics can be used in severe pain.
[12]
 Surgical intervention and 
physical therapy may help to control pain in hemophilia.
[15]
 
1.2. FACTOR VIII: 
1.2.1. Factor VIII Physiology: 
FVIII is a critical blood coagulation factor. It is a complex glycoprotein consisting of 
2,351 amino acids.
[1]
 FVIII is considered one of the largest blood coagulation factors.
[1]
 FVIII is 
produced mainly by hepatocytes; however, it is produced in small amounts by sinusoidal 
endothelial cells, glomerular cells, tubular endothelial cells and lymphatic tissues.
[1,16]
 FVIII is 
the least stable blood coagulation factor.
[1]
 It is highly susceptible to plasma proteolytic 
degradation facilitated through phospholipid-binding proteases, e.g., activated protein C and 
activated factor X (FXa).
[1,17]
 FVIII is also susceptible to cellular uptake into hepatocytes and 
macrophage-like Kupffer cells in the liver.
[17]
 FVIII cellular uptake is facilitated by a number of 
receptors and other cell membrane components expressed mainly on hepatocytes and to some 
extent on Kupffer cells, including low density lipoprotein receptor (LDLR), LDLR-related 
protein-1 (LRP1), heparan-sulfate proteoglycans (HSPG), megalin, asialoglycoprotein receptor 
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(ASGPR) and unidentified carbohydrate receptors.
[17]
 In plasma, FVIII circulates with a tight, 
non-covalent bond to vWF, which acts as its carrier.
[1,17]
 The biological functions of vWF as 
FVIII carrier include FVIII heterodimeric structure stabilization, FVIII plasma proteolytic 
degradation prevention and FVIII hepatic cellular uptake inhibition.
[17]
 
1.2.2. Factor VIII Replacement Therapy: 
FVIII replacement therapy in hemophilia revolves around three clinical strategies: 
primary prophylaxis, secondary prophylaxis and on-demand treatment (Table 1.4).
[18]
 Primary 
FVIII prophylaxis is a long-term therapy on a continuous basis initiated either ‘after the first 
episode of joint bleeding and before 2 years of age’ or ‘before 2 years of age without any joint 
bleeding episode.’[18] Secondary FVIII prophylaxis may consist of either long-term or short-term 
prophylaxis.
[18]
 Long-term secondary FVIII prophylaxis is a continuous therapy initiated either 
‘after two episodes of joint bleeding’ or ‘at >2 years of age.’[18] Short-term FVIII prophylaxis is 
an intermittent therapy initiated after frequent bleeding episodes.
[18]
 On-demand FVIII treatment 
is a therapy initiated only upon the occurrence of bleeding and until it stops.
[18]
 
Table 1.4. Clinical Strategies for FVIII Replacement Therapy
[18] 
Strategy FVIII Replacement Therapy 
Primary prophylaxis  
Long-term (continuous)  
By bleeding • After the first joint bleeding and before the 2 years of age 
By age • Before the 2 years of age without any joint bleeding episode 
Secondary prophylaxis  
Long-term (continuous)  
By bleeding • After two episodes of joint bleeding 
By age • At >2 years of age 
Short-term (intermittent) • After frequent bleeding episodes 
On-demand treatment • Upon the occurrence of bleeding 
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1.2.3. Factor VIII Products: 
FVIII products are either plasma-derived or recombinant proteins. There are various 
pdFVIII products licensed in the United States (Table 1.5).
[19–24]
 The first pdFVIII product was 
introduced in the 1960s.
[25]
 Isolated from thousands of blood donors, pdFVIII products carry a 
potential risk of transmitting infection.
[3,12,25]
 Several reports of viral transmission, especially 
human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in the 1980s, were 
documented.
[12,25,26]
 However, current technologies ensure the safety of pdFVIII products 
through vigorous purification and viral inactivation procedures.
[12,25,26]
 
Table 1.5. pdFVIII Products Licensed in the United States 
Brand Name Manufacturer or Distributer Site 
Alphanate
[19]
 Grifols Biologicals Inc Los Angeles, CA 
Hemofil M
[20] 
Baxter Healthcare Corp Westlake Village, CA 
Humate-P
[21]
 CSL Behring LLC Kankakee, IL 
Koāte-DVI[22] Talecris Biotherapeutics Inc Research Triangle Park, NC 
Monarc-M
[23]
 Baxter Healthcare Corp Westlake Village, CA 
Monoclate-P
[24]
 CSL Behring LLC Kankakee, IL 
According to FVIII:C content per total protein milligram (mg), pdFVIII products are 
classified into four classes: low-, intermediate-, high- and ultrahigh-purity (Table 1.6).
[25]
 Single-
donor-cryoprecipitate is the only existing low-purity pdFVIII product.
[25]
 It contains FVIII:C <5 
international units per milligram (IU mg
-1
) of protein.
[25]
 Single-donor-cryoprecipitate is no 
longer used whenever other FVIII products are available due to absence of viral inactivation and 
purification procedures throughout its production.
[25]
 Intermediate-purity pdFVIII products 
contain FVIII:C between 1–10 IU mg-1 of protein.[25] High-purity pdFVIII products contain 
FVIII:C between 50–1,000 IU mg-1 of protein.[25] Ultrahigh-purity pdFVIII products contain 
FVIII:C of 3,000 IU mg
-1
 of protein.
[25]
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Table 1.6. pdFVIII Products Classification
[25] 
Purity 
FVIII:C Content 
(IU mg
-1
 of Protein) 
Low <5 
Intermediate 1–10 
High 50–1,000 
Ultrahigh 3,000 
Several rFVIII products are licensed in the United States (Table 1.7).
[27–32]
 The first 
rFVIII product was produced in 1984.
[12,33]
 Utilizing mammalian cells transfected with human 
FVIII gene, rFVIII products are produced from advanced deoxyribonucleic acid (DNA) 
technologies.
[12,33]
 Since rFVIII products are not derived from blood donors, they carry a 
minimal risk of infection transmission.
[12,33]
 Therefore, rFVIII products are generally preferred 
over pdFVIII products whenever they are available. There is still a low risk of viral infection, 
theoretically, with some rFVIII products that contains human albumin or utilize it throughout 
their production.
[25,33]
 Therefore, rFVIII products undergo viral inactivation and purification 
procedures although HIV and HCV transmission have never been documented with the use of 
rFVIII products.
[12,25,33]
 
Table 1.7. rFVIII Products Licensed in the United States 
Brand Name Manufacturer or Distributer Site 
Advate
[27] 
Baxter Healthcare Corp Westlake Village, CA 
Helixate FS
[28] 
CSL Behring LLC Kankakee, IL 
Kogenate FS
[29] 
Bayer HealthCare LLC Tarrytown, NY 
Recombinate
[30] 
Baxter Healthcare Corp Westlake Village, CA 
ReFacto
[31] 
Wyeth Pharmaceuticals Inc Philadelphia, PA 
Xyntha
[32] 
Wyeth Pharmaceuticals Inc Philadelphia, PA 
Based on utilization of human albumin in the cell culture and type of the stabilizer used, 
rFVIII products are classified into three classes: first-, second- and third-generation.
[12,26,33]
 First-
 12 
generation FVIII products utilize human albumin in their cell culture and use it as a 
stabilizer.
[12,33]
 Second-generation FVIII products are stabilized using sucrose.
[12,33]
 However, 
they utilize human albumin in their cell culture.
[12,33]
 Third-generation FVIII products are 
stabilized using sucrose or trehalose.
[33]
 They do not utilize human albumin.
[12,33]
 
Table 1.8. rFVIII Products Licensed in the United States
[12,33]
 
Generation Human Albumin in the Cell Culture Stabilizer 
First Yes Human albumin 
Second Yes Sucrose 
Third No Sucrose or trehalose 
1.2.4. Factor VIII Dosing: 
Current FVIII prophylactic dosing revolves around achieving a trough plasma FVIII:C ≥1 
IU dL
-1
.
[3]
 For this purpose, the recommended FVIII routine prophylactic dose ranges from 25–
40 international units per kilogram (IU kg
-1
) three times per week.
[3]
 The FVIII routine 
prophylactic dose may be modified empirically. For treatment of acute bleeding episodes, a 
FVIII loading dose, expressed in IU kg
-1
, is calculated as 50% of the required elevation in plasma 
FVIII:C, expressed in IU dL
-1
 (Equation 1.1).
[3,34]
 
 
(Desired FVIII:C Baseline Plasma FVIII:C)
FVIII Loading Dose
2

 ... (Equation 1.1)[3,34] 
Equation 1.1 assumes that each 1 IU kg
-1
 of the FVIII loading dose will elevate plasma FVIII:C 
by 2 IU dL
-1
.
[34]
 Table 1.9 shows the recommended guidelines for the desired plasma FVIII:C 
and the duration of FVIII therapy in different acute bleeding types.
[25,34]
 Since the baseline 
plasma FVIII:C is usually very low, it may be excluded from Equation 1.1.
[34]
 A FVIII 
maintenance dose is calculated as 50% of the FVIII loading dose and given every 12-hours (h) to 
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maintain the desired plasma FVIII:C over the recommended duration of FVIII therapy.
[34]
 The 
recommended FVIII routine prophylactic dose (25–40 IU dL-1 three times per week) should be 
resumed after the treatment of acute episodes. 
Table 1.9. Recommended Guidelines for FVIII Therapy in Acute Bleeding
[25,34] 
Bleeding Site or Type 
Plasma FVIII:C 
(IU dL
-1
) 
Duration of FVIII Therapy 
(Day) 
Mucosa 30 1–2 
Joint 50 Up to 7 
Muscle 50 Up to 7 
Gastrointestinal 50–100 10–14 
Genitourinary 50–100 10–14 
Central nervous system (CNS) 50–100 10–14 
Trauma 50–100 Up to 14 
Surgery 50–100 Up to 14 
1.2.5. Factor VIII Pharmacokinetic Characteristics: 
FVIII follows linear pharmacokinetic (PK) characteristics.
[3]
 After a single short infusion 
of FVIII, the decline in the terminal β phase (disposition part) of the plasma FVIII:C-time profile 
exhibits a monoexponetial and a linear pattern on the linear and the logarithmic scale, 
respectively, thereby indicating a first-order kinetics and a linear PK.
[3]
 A continuous infusion of 
FVIII produces a sustained plasma FVIII:C over the infusion duration that is proportional to 
FVIII infusion rate, thus demonstrating a linear PK.
[3]
 Standard FVIII PK parameters, including 
volume of distribution at steady-state (Vss), total clearance (CLtot), terminal half-life (t1/2), and 
mean residence time (MRT) are constant among different doses of FVIII, therefore representing 
dose-independent properties and a linear PK.
[3]
 FVIII PK linearity was established for a dose 
range from 25–100 IU kg-1.[3] 
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Standard FVIII PK parameters from representative single short infusion PK studies of 
FVIII in hemophilia are shown in Table 1.10.
[3,35–40]
 FVIII:C Vss ranges from 43–57 milliliters 
per kilogram (mL kg
-1
).
[3,35–40]
 Therefore, FVIII remains in the vascular system with only a small 
fraction distributed extravascularly.
[3]
 FVIII:C CLtot ranges from 2.4–3.4 milliliters per hour per 
kilogram (mL h
-1
 kg
-1
).
[3,35–40]
 FVIII clearance (CL) pathways have not been extensively 
investigated. FVIII is cleared by plasma phospholipid-binding proteases.
[17]
 FVIII is also cleared 
by cellular uptake into hepatocytes and macrophage-like Kupffer cells.
[17]
 FVIII is a large 
glycoprotein; therefore, it does not undergo renal clearance.
[41]
 FVIII:C t1/2 ranges from 11–16 
h.
[3,35–40]
 FVIII:C MRT ranges from 14–21 h.[3,35–40] FVIII unbound fraction (fu) in plasma has 
not been comprehensively studied.
[42]
 The plasma ratio of FVIII to vWF is 1:50.
[42]
 Since FVIII 
circulates in plasma non-covalently bound to vWF, vWF may theoretically bind all FVIII 
molecules in plasma.
[42]
 Consequently, a negligible FVIII fu may remain in plasma that is rapidly 
cleared by plasma proteolytic degradation or by hepatic cellular uptake. 
Table 1.10. Previously Reported Standard FVIII PK Parameters
[3] 
Study 
Vss 
(mL kg
-1
) 
CLtot 
(mL h
-1
 kg
-1
) 
t1/2 
(h) 
MRT 
(h) 
pdFVIII 
Smith et al.
[35] 
44 3.4 14 14 
Schwartz et al.
[36] 
57 3.2 14 18 
Kasper et al.
[37] 
49 2.5 15 21 
Björkman et al.
[38] 
54 2.9 14 19 
Knevelman et al.
[39] 
43 2.4 14 20 
Fijnvandraat et al.
[40]
 43 2.9 11 16 
rFVIII 
Schwartz et al.
[36] 
51 2.5 16 21 
Fijnvandraat et al.
[40] 
45 3.2 11 16 
Variability in FVIII PK characteristics has been identified.
[3,43–47]
 Critical factors that 
contribute to this variability include vWF, blood group, age, bodyweight, medical states, FVIII 
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inhibitory antibodies, FVIII assays and FVIII products (pdFVIII versus rFVIII).
[3,43–47]
  
Endogenous and pre-infused vWF can influence FVIII PK characteristics since vWF stabilizes 
FVIII heterodimeric structure, prevents FVIII plasma proteolytic degradation and inhibits FVIII 
hepatic cellular uptake.
[3,43]
 Patients with von Willebrand disease (vWD) exhibit low or defective 
endogenous vWF, and therefore a high FVIII:C CLtot has been observed in these patients.
[3,43]
 
Pre-infused vWF has been shown to have a negative correlation with FVIII:C CLtot.
[3,43]
 Blood 
group may influence FVIII PK characteristics secondary to coexistence of different vWF plasma 
levels in different blood groups.
[3,43]
 For instance, blood group O hemophiliacs have been shown 
to have a high FVIII:C CLtot that may be explained by presence of a low vWF plasma level. 
[3,43]
 
Age and bodyweight may influence FVIII PK characteristics due to different physiological 
changes related to changes in these two factors.
[3,43]
 Both age and bodyweight have been shown 
to have a negative correlation with FVIII:C CLtot.
[3,43]
 Different medical states may influence 
FVIII PK characteristics secondary to pathophysiological changes affecting FVIII. For instance, 
a low FVIII:C CLtot has been observed postoperatively that is explained by a subsequent increase 
in vWF plasma level due to FVIII continuous infusion during surgery.
[43,44]
 FVIII inhibitory 
antibodies can influence FVIII PK characteristics by rapid inactivation of infused FVIII therapy, 
thereby resulting in a high FVIII:C Vss and CLtot.
[45]
 
FVIII assays play a critical role in FVIII PK variability.
[46]
 Different FVIII assays are 
available, e.g., one-stage clotting, two-stage clotting and chromogenic substrate assays.
[46]
 
Different reference standards are available, e.g., international standards and product-specific 
standards.
[46]
 Different assay equipment (coagulometer) and procedures (dilutions) are 
available.
[46]
 Variation in FVIII assays is a major source of FVIII PK discrepancy.
[46]
 For 
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instance, one-stage clotting assays have been shown generally to result in 20–50% lower plasma 
FVIII:C than that obtained by chromogenic substrate assays.
[47]
 
Variability in FVIII PK characteristics between pdFVIII and rFVIII products have been 
investigated in many crossover studies.
[3,43]
 This variability rFVIII is generally consistent among 
different bioequivalence studies in hemophilia, especially under stable physiological 
conditions.
[3,43]
 In general, FVIII:C Vss and CLtot of pdFVIII products were significantly higher 
than those of rFVIII products.
[3,43]
 Variability in FVIII:C Vss and CLtot led to a marginal 
variability in FVIII:C MRT and t1/2, i.e., a shorter FVIII:C MRT and t1/2 of pdFVIII products 
compared to those of rFVIII products.
[3,43]
 In contrast to these findings, a modest variability in 
FVIII:C Vss and CLtot with no influence on FVIII:C MRT and t1/2 was reported in one study
[42]
 (a 
lower FVIII:C Vss and CLtot of the pdFVIII product compared to those of the rFVIII 
product).
[3,43]
 Variability in FVIII PK characteristics may be related to differences in 
manufacturing procedures, purity levels and pharmaceutical contents. Differences in protocols, 
blood sampling schedules and FVIII assays may also influence the results of different 
bioequivalence studies.
[3,43]
 
1.3. BLOOD COAGULATION CASCADE MODEL: 
The cascade (or waterfall) model of blood coagulation is the classical model of 
hemostasis.
[48–50]
 It demonstrates a sequential activation of various blood coagulation 
contributors in a dependent way.
[48–51]
 Originally, the cascade model of blood coagulation was 
viewed as conversion of blood coagulation contributors, initially known as blood coagulation 
factors, from their proenzymatic forms to their active enzymatic forms.
[48,51]
 The original cascade 
model of blood coagulation was consequently adjusted to include the fact that some blood 
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coagulation contributors do not have an enzymatic activity, i.e., they act as blood coagulation 
cofactors.
[48,51]
 The cascade model of blood coagulation includes three pathways: intrinsic, 
extrinsic and common (Figure 1.4).
[34]
 The intrinsic and extrinsic pathways are independent of 
each other, and they end with the common pathway.
[49]
 The endpoint of these pathways is a burst 
of thrombin, also known as activated factor II (FIIa), leading to formation of an insoluble fibrin 
mass.
[,48,49,51]
 
Figure 1.2. Blood Coagulation Cascade Model
[34]†
 
 
†
Modified from its original format 
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1.3.1. Intrinsic Pathway: 
The intrinsic pathway is initiated by blood coagulation contributors that are normally 
located within the vasculature.
[49]
 High molecular weight kininogen (HMWK) converts factor 
XII (FXII) to activated factor XII (FXIIa) when FXII comes in contact with a negatively charged 
surface in blood, e.g., an activated platelet.
[49]
 The small amount of FXIIa converts prekallikrein 
to kallikrein.
[49]
 Kallikrein, along with HMWK, converts further FXII to FXIIa in an accelerated 
speed.
[49]
 Both FXIIa and HMWK converts factor XI (FXI) to activated factor XI (FXIa).
[49]
 
FXIa, in turn, converts factor IX (FIX) to activated factor IX (FIXa).
[49]
 FIXa and two later 
products, FXa and thrombin, converts FVIII to activated factor VIII (FVIIIa).
[49]
 Finally, FIXa, 
FVIIIa and a negatively charged phospholipid (found on cell membranes) in presence of calcium 
ions (Ca
2+
) form a complex known as tenase.
[49]
 Tenase is able to convert factor X (FX) to 
FXa.
[49]
 The intrinsic pathway proceeds to the common pathway with this step.
[49]
 
1.3.2. Extrinsic Pathway: 
The extrinsic pathway is initiated by blood coagulation contributors that are normally 
located outside the vasculature.
[49]
 Upon an injury, tissue factor (TF) is released from the 
endothelium.
[49]
 TF converts factor VII (FVII) to activated VII (FVIIa).
[49]
 TF binds to FVIIa, 
forming a complex.
[49]
 The formed TF/FVIIa complex has a similar capability of tenase, i.e., it is 
able to converts FX to FXa.
[49]
 The extrinsic pathway proceeds to the common pathway with this 
step.
[49]
 
1.3.3. Common Pathway: 
The common pathway is initiated at the end of the intrinsic pathway and/or the extrinsic 
pathway.
[49]
 Tenase from the intrinsic pathway or TF/FVIIa complex from the extrinsic pathway 
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convert FX to FXa.
[49]
 Factor V (FV) is converted to activated factor V (FVa) by a later product, 
thrombin.
[49]
 FXa, FVa and a negatively charged phospholipid (found on cell membranes) in 
presence of Ca
2+
 form a complex known as prothrombinase.
[49]
 Prothrombinase converts 
prothrombin, also known as factor II (FII), to thrombin.
[49]
 Finally, thrombin converts fibrinogen 
to an insoluble fibrin mass.
[49]
 
1.3.4. Blood Coagulation Cascade Model in Hemophilia A: 
In hemophilia, FVIII is unavailable in the intrinsic pathway.
[34]
 Subsequent to FVIII 
unavailability, FVIIIa is unavailable in the intrinsic pathway as well. Unavailability of FVIIIa 
results in absence of tenase at the end of the intrinsic pathway. Tenase is a critical element of the 
common pathway. It is required for activation of the first reaction, and therefore its absence leads 
to absence of the insoluble fibrin mass at the end of the common pathway. Consequently, 
hemophiliacs bleed spontaneously due to FVIII deficiency. 
1.4. BLOOD COAGULATION CELL-BASED MODEL: 
The cell-based model of blood coagulation is the modern model of hemostasis.
[48–51]
 It 
exhibits the interdependent interaction between various blood coagulation contributors.
[48–51]
 It 
emphasizes on the role of cells, e.g., TF-bearing cells and platelets, in the blood coagulation 
process.
[48–51]
 Therefore, it adds more details to in vivo hemostasis.
[48–51]
 The cell-based model of 
blood coagulation includes three phases: initiation, amplification and propagation (Figure 
1.5).
[48]
 Similar to the cascade model but with a sophisticated remodeling, the endpoint of the 
cell-based model of blood coagulation is a sustained thrombin generation, leading to formation 
of a critical, insoluble fibrin matrix between activated platelets.
[48–51]
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Figure 1.3. Blood Coagulation Cell-Based Model
[48]†
 
 
†
Modified from its original format 
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1.4.1. Initiation Phase: 
Cells expressing TF are localized outside the vasculature, which prevents initiation of 
blood coagulation under normal conditions.
[48,50,51]
 Upon injury, blood becomes exposed to TF-
bearing cells, and thus begins the initiation phase.
[48,50,51]
 FVIIa, the only blood coagulation 
factor circulating routinely in blood in its active form, binds to the exposed TF.
[48,50,51]
 TF/FVIIa 
complex activates FIX and FX.
[49,50,51]
 FXa activates its cofactor, FV.
[49,50,51]
 FXa then associates 
with FVa, forming prothrombinase on the surface of TF-bearing cells.
[48,50,51]
 Finally, 
prothrombinase cleaves prothrombin to thrombin, and the initiation phase proceeds to the 
amplification phase.
[48,50,51]
 
1.4.2. Amplification Phase: 
The blood coagulation process progresses to its amplification phase when the vasculature 
damage permits platelets and larger proteins to diffuse into the extravascular site and attach to 
TF-bearing cells.
[48,50,51]
 The insignificant amount of thrombin formed in the initiation phase has 
several functions in the amplification phase.
[48,50,51]
 First, it activates FV, which binds to the 
surface of platelets.
[48,50,51]
 FVa is also released from platelets in its active form.
[48,50,51]
 In 
addition, thrombin dissociates FVIII/vWF complex into FVIIIa, which binds to the surface of 
platelets, and free vWF, which mediates further adhesion and aggregation to platelets.
[48,50,51]
 
Furthermore, thrombin activates FXI on the surface of platelets.
[48,50,51]
 Finally, thrombin 
activates platelets, exposing their receptors to the activated blood coagulation contributors, and 
the amplification phase proceeds to the propagation phase.
[48,50,51]
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1.4.3. Propagation Phase: 
The propagation phase takes place on the surface of activated platelets.
[48,50,51]
 FIXa, 
generated in the initiation phase or being generated through platelet-bound FXIa, binds to FVIIIa 
on the activated platelet surface forming tenase.
[48,50,51]
 Tenase activates FX.
[48,50,51]
 FXa binds to 
platelet-bound FVa, forming additional prothrombinase with adequate activity to generate 
additional thrombin in an accelerated speed.
[48,50,51]
 Formation of thrombin in an accelerated 
speed results in dissociation of fibrinopeptide A from fibrinogen, thereby leading to formation of 
a critical, insoluble fibrin matrix between activated platelets.
[48,50,51]
 
1.4.4. Blood Coagulation Cell-Based Model in Hemophilia A: 
In hemophilia, the initiation phase occurs in a normal fashion. However, the 
amplification phase is incomplete due to FVIII deficiency. This results in deficient tenase 
generation in the propagation phase. Deficient tenase generation prevents self-sustaining 
production of FXa needed to produce a sufficient amount of prothrombinase. Lacking of 
prothrombinase generation, therefore, prevents further thrombin burst necessary for additional 
platelets activation and fibrin formation. Subsequently, patients with hemophilia experience 
spontaneous bleeding. 
1.5. APPLICATION OF BLOOD COAGULATION CASCADE MODEL IN 
HEMOPHILIA A: 
The cascade model of blood coagulation has been utilized to screen hemophilia and 
assess its severity.
[52,53]
 It has also been utilized to quantify FVIII replacement therapy 
pharmacodynamic (PD) response as well as its PK characteristics.
[52,53]
 For these purposes, both 
aPTT and FVIII:C have been used extensively. 
[52–54]
 Hemophilia requires assessment of blood 
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coagulation through the intrinsic and common pathways because FVIII, the deficient blood 
coagulation contributor, is a part of the intrinsic pathway, and its deficiency has a large effect on 
the common pathway endpoint, fibrin.
[54]
 Therefore, absence of TF, a critical blood coagulation 
contributor in the extrinsic pathway, from aPTT and FVIII:C assays allow exclusive assessment 
of blood coagulation through the intrinsic and common pathways.
[54]
 Both aPTT and FVIII:C are 
measured within the plasma matrix.
[52–54]
 
1.5.1. Activated Partial Thromboplastin Time: 
Assays of aPTT involve two phases.
[52]
 The first phase is called the contact activation 
phase.
[52]
 It includes the first reaction of the intrinsic pathway to obtain FXIIa.
[52]
 The contact 
activation phase is initiated by pre-incubating the citrated plasma sample with blood coagulation 
activators.
[52]
 Blood coagulation activators includes artificial contact activators, e.g., ellagic acid 
,celite, kaolin or silica, that create surfaces with negative charges for the reactions to occur.
[52]
 
Phospholipids are also included as blood coagulation activators in the contact activation phase; 
however, they are not involved in activation of blood coagulation until the second phase.
[52]
 The 
second phase is called the re-calcification phase.
[52]
 It includes the rest of the reactions in the 
intrinsic and common pathways, resulting in a fibrin clot.
[52]
 The re-calcification phase is 
initiated by adding calcium chloride (CaCl2) that provides Ca
+2
.
[52]
 Ca
+2
 are involved in different 
reactions and necessary to reverse the anticoagulant effect of citrate in the plasma sample.
[52]
 The 
formed fibrin clot density in the plasma sample is detected optically (common) or mechanically 
(less common) by automated methods, and aPTT is recorded.
[52,54]
 Reference aPTT values range 
from 25–38 seconds (sec).[54] In hemophilia, aPTT is severely prolonged.  
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1.5.2. FVIII Coagulant Activity: 
Like other blood coagulation factors, FVIII cannot be quantified by physiochemical 
assays due to its complex structure and function.
[55]
 However, two quantification techniques have 
been developed utilizing two major moieties of FVIII complex: FVIII:C and factor VIII antigen 
(FVIII:Ag).
[56]
 FVIII:C possesses the active biological function, and therefore it is quantified by 
bioassays that utilize the cascade model of blood coagulation.
[55,56]
 These bioassays quantify 
FVIII:C in an indirect manner since the FVIII is a proenzyme that possesses no direct enzymatic 
activity.
[53]
 Three FVIII:C bioassays are available: one-stage clotting, two-stage clotting and 
chromogenic substrate.
[53]
 These assays, especially one-stage clotting assays, are common in 
clinical settings.
[47]
 FVIII:Ag is inactive, and its amount is equivalent to that of FVIII:C.
[56]
 
FVIIII:Ag is quantified by immunoassays.
[56]
 FVIII:Ag immunoassays are irrelevant to the 
cascade model of blood coagulation and rarely being used in clinical settings. 
Principles and techniques of one-clotting assays are similar to aPTT assays.
[47,53]
 One-
stage clotting assays quantify FVIII ability to shorten aPTT in one step.
[47,53]
 One-stage clotting 
assays utilize the intrinsic and common pathways to quantify aPTT as described before. 
However, they assume that FVIII, the deficient coagulation contributor in hemophilia, is rate-
limiting in the plasma sample with all blood coagulation contributors available at their saturating 
levels.
[53]
 One-stage clotting assays also assume that there is a straight mathematical relationship 
between aPTT and FVIII:C, and therefore FVIII:C can be obtained by matching the assay aPTT 
to a reference using a standard plasma FVIII:C-aPTT profile on a logarithmic scale.
[57]
 A major 
limitation of the one-stage clotting assays is feedback activation of FVIII in the intrinsic pathway 
by thrombin formed in the common pathway.
[53]
 One-stage clotting assays are the most 
commonly used in clinical settings.
[47]
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Principles and techniques of two-stage clotting assays are similar to that of one-stage 
clotting assays with few modifications, though.
[47,53,57]
 In two isolated steps, two-stage clotting 
assays quantify FVIII ability to potentiate FX activation with subsequent prothrombinase 
formation by measuring the rate of fibrin formation.
[47,53,57]
 The first step includes all the 
reactions in the intrinsic pathway and the first few reactions in the common pathway necessary to 
form FXa and prothrombinase.
[47,53,57]
 The first step is initiated by pre-incubating the citrated 
plasma sample with phospholipids, CaCl2, FV, FIX, FX, FXI, FXII and aluminum hydroxide 
(Al[OH]3).
[53,57]
 FV, FIX, FX, FXI and FXII are added to guarantee that FVIII, the deficient 
blood coagulation contributor, is rate-limiting for FXa and prothrombinase formation in the 
plasma sample, and therefore the amount of FXa and prothombinase are proportional to the 
amount of FVIII in the plasma sample. Al(OH)3 adsorbs prothrombin from the plasma sample, 
which prevents progression of blood coagulation beyond FXa and prothombinase formation in 
the first step, thereby preventing feedback activation of FVIII in the intrinsic pathway by 
thrombin formed in the common pathway.
[57]
 The second step includes the rest of reaction in the 
common pathway after FXa and prothrombinase formation and until fibrin formation.
[47,53]
 It is 
initiated by adding prothrombin and fibrinogen to the plasma sample.
[57]
 Fibrin formation is 
detected optically or mechanically by automated methods. Fibrin formation time is recorded 
accordingly.
[57]
 As for one-stage clotting assays, two-stage clotting assays assume that there is a 
direct mathematical relationship between fibrin formation time and FVIII:C, and therefore 
FVIII:C can be obtained by matching the assay fibrin formation time to a reference using a 
standard plasma FVIII:C-fibrin formation time profile on a logarithmic scale.
[57]
 Due to the 
complexity with automation of two-stage clotting assays, they are not commonly used.
[58]
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Principles and techniques of chromogenic substrate assays involves two steps as 
described before for the two-stage clotting assays with, however, an adjusted detection 
method.
[47,53,57]
 The detection method includes addition of a chromogenic substrate for FXa in 
the second step.
[53]
 FXa cleaves the chromogenic substrate, and the color reaction (absorbance) is 
measured spectrophotometrically.
[47,53,57]
 The color intensity is proportional to the amount of 
FXa, which is proportional to the amount of FVIII in the plasma sample (assuming that FVIII is 
rate-limiting for FXa formation in the first step), and FVIII:C can be calculated 
accordingly.
[47,53,57]
 Whenever chromogenic substrate assays are available, they are favored over 
two-stage clotting assays due their less complex automation. 
1.6. APPLICATION OF BLOOD COAGULATION CELL-BASED MODEL IN 
HEMOPHILIA A: 
The cell-based model of blood coagulation has been utilized to develop different assays 
that provide biomarkers assessing global hemostasis.
[59,60]
 Under ex vivo environment, their 
principles and techniques mimic in vivo blood coagulation.
[59,60]
 Therefore, global hemostasis 
biomarkers can potentially assess the hemostatic state and quantify FVIII replacement therapy 
PD response in hemophilia. Global hemostasis biomarkers are classified into two classes: platelet 
function and blood viscoelasticity.
[59,60]
 Platelet function is assessed using Hemostasis Analysis 
System (HAS) that provides platelet contractile force (PCF), clot elastic modulus (CEM) and 
force onset time (FOT).
[59]
 Blood viscoelasticity can be assessed by Thromboelastography (TEG) 
that provides reaction-time (R), kinetics-time (K) and maximum amplitude (MA).
[60]
 Global 
hemostasis biomarkers have been validated in different thrombotic and non-thrombotic 
disorders, including hemophilia.
[59–69]
 Platelet function and blood viscoelastic biomarkers are 
measured within the whole blood matrix.
[59,60]
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1.6.1. Platelet Function Biomarkers: 
Platelets play a critical role in the cell-based model of blood coagulation.
[48–51]
 Fibrin 
polymers connect activated platelets at the end of the blood coagulation process.
[48–51]
 Therefore, 
assessment of platelet function by HAS may be critical in hemophilia, reflecting the entire blood 
coagulation contributors, including FVIII. Blood coagulation in HAS is initiated by re-
calcification of a citrated whole blood sample in a thermostated analyzer cup, and platelet 
function is assessed over 20 minutes (min).
[61]
 The re-calcification provides Ca
+2
 that are 
involved in different blood coagulation reactions and necessary to reverse the anticoagulant 
effect of citrate in the whole blood sample.
[52]
 As HAS is running, an upper plate centered above 
the analyzer cup containing the whole blood sample is lowered.
[61]
 As the clot develops, the clot 
adheres to the exposed surface of the analyzer cup and the upper plate.
[61]
 As fibrin is formed 
between platelets, platelets pull the fibrin polymers to the center generating force to the clot that 
is attached to the surface of the analyzer cup and the upper plate.
[61]
 A transducer attached to the 
upper plate generates electrical signals (measured as kilodynes [kdynes]) proportional to the 
platelets contractions, which are recorded continuously throughout the assay time.
[61]
 These 
records are known as PCF.
[61]
 
A descending force with a specific magnitude is also applied to the upper plate.
[61]
 The 
extent of the descending displacement resulted from the force is determined.
[61]
 The ratios of the 
descending force to the descending displacement (measured in kilodynes per centimeter square 
[kdynes cm
-2
]) are computed throughout the assay time.
[61]
 These ratios indicate the elasticity of 
the formed clot between the analyzer cup and the upper plate.
[61]
 These ratios are known as 
CEM.
[61]
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Re-calcification of the whole blood sample results in initial thrombin generation since 
blood coagulation is initiated immediately.
[61]
 The initial amount of thrombin generated in the 
whole blood sample between the analyzer and the upper plate is essential for initial platelets 
contractions, which is indicated by initially recorded PCF.
[61]
 Therefore, the lag time before 
initially recorded PCF indicates the time required to generate thrombin.
[61]
 This lag time is 
known as FOT.
[61]
 FOT is determined from the PCF-time profile by observing the first spike in 
PCF
[61]
 
Platelet function biomarkers, including PCF, CEM and FOT, quantify in vivo blood 
coagulation.
[59,61]
 PCF is the force generated by platelets throughout clot retraction.
[59,62–64]
 PCF 
is sensitive to platelets (number and metabolic status), thrombin, antithrombins and glycoprotein 
IIb/IIIa (GPIIb/IIIa) platelet receptor status.
[59,62–67]
 CEM reflects clot structural firmness.
[59,62–64]
 
CEM is sensitive to platelets (number and force), thrombin generation rate, fibrinogen 
concentration, red blood cell (RBC) flexibility and changes in clot structure.
[59,62–66]
 FOT, also 
referred to as thrombin generation time (TGT), is the time in which thrombin is produced in 
whole blood.
[59,61–64]
 FOT reflects clotting initiation.
[59,61–64]
 FOT is estimated from PCF 
kinetics.
[59,61–64]
 As PCF is thrombin-dependent, the initial spike in PCF, indicated by FOT, is a 
measure of thrombin generation.
[59,61–64]
 FOT is sensitive to blood coagulation factor deficiencies 
and inhibitors, as well as antithrombins.
[59,62]
 Reference ranges for platelets function biomarkers 
are shown in Table 1.11.
[63]
 Significantly low PCF, low CEM and prolonged FOT are related to 
increased risk of bleeding, e.g., hemophilia, while significantly high PCF, high CEM and 
shortened FOT are related to increased risk of thrombosis, e.g., coronary artery disease 
(CAD).
[59]
 Figure 1.4 shows platelet function biomarkers in different conditions.
[63]
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Table 1.11. Reference Ranges for Platelet Function Biomarkers
[63] 
Biomarker Reference Range 
PCF (kdynes) 4.8–9.5 
CEM (kdynes cm
-2
) 14.0–35.0 
FOT (min) 3.0–8.0 
 
Figure 1.4. Platelet Function Biomarkers in Different Conditions
[63] 
 
1.6.2. Blood Viscoelastic Biomarkers: 
Fibrin polymers formed at the end of the cell-based model of blood coagulation causes 
changes in blood viscoelasticity.
[60]
 Consequently, assessment of blood viscoelasticity by TEG 
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may be vital in hemophilia, catching changes in the blood coagulation contributors, including 
FVIII. Blood coagulation in TEG is initiated by transferring a citrated whole blood sample pre-
mixed with blood coagulation activators, e.g., phospholipids and an artificial contact activator 
(kaolin), to a thermostated analyzer cup containing CaCl2, and blood viscoelasticity is assessed 
over time.
[60,70]
 The artificial contact activator creates surfaces with negative charges for the 
blood coagulation reactions to occur.
[52]
 Phospholipids are involved in many reactions.
[48–51]
 
CaCl2 is a source of Ca
+2
, which are involved in different reactions and necessary to reverse the 
anticoagulant effect of citrate in the whole blood sample.
[52]
 As TEG is running, the analyzer cup 
oscillates backward and forward at a constant speed.
[60,71]
 A stationary pin connected to a torsion 
wire is suspended in the analyzer cup containing the whole blood sample.
[60,71]
 As the clot 
develops, the resistance changes and the analyzer cup motions are detected over time by the 
stationary pin.
[60,71,72]
 The pin transmits the detected motions to a computer that graphically 
represents clot development, and blood viscoelastic biomarkers are calculated (Figure 
1.5).
[72,73,74]
 
Figure 1.5. TEG Tracing with Blood Viscoelastic Biomarkers
[74]† 
 
†
Modified from its original format 
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Blood viscoelasticity assessed by TEG includes two phase: blood coagulation and 
fibrinolysis.
[74]
 Routinely reported blood viscoelastic biomarkers include R, K and MA from the 
blood coagulation phase.
[71]
 R is the lag time before initial clot formation.
[63]
 R is actually the 
time between transferring the whole blood sample to the analyzer cup and an initial signal of 2 
millimeters (mm) amplitude.
[63]
 Therefore, R indicates the rate of fibrin production and cross-
linking.
[63]
 K is the time between initial clot formation to integrated clot development.
[60]
 K is 
actually the time the initial signal of 2 mm amplitude to a signal of 20 mm amplitude.
[63]
 
Therefore, K expresses the dynamic of clot development and propagation.
[63]
 MA quantifies the 
maximum integrated fibrin clot (strength and stability).
[60,63]
 MA is actually the maximum height 
of the TEG trace.
[60]
 MA is largely dependent on plasma fibrinogen content and platelet count.
[63]
 
Therefore, MA is also dependent on fibrin (content and structure) and platelet concentration.
[63]
 
Reference ranges for blood viscoelastic biomarkers are shown in Table 1.12.
[63]
 Significantly 
prolonged R, prolonged K and decreased MA are related to increased risk of bleeding, e.g., 
hemophilia, while significantly shortened R, shortened K and increased MA are related to 
increased risk of thrombosis, e.g., deep vein thrombosis (DVT).
[60,71]
 Figure 1.6 shows TEG 
tracing in different conditions.
[71]
 
Table 1.12. Reference Ranges for Blood Viscoelastic Biomarkers
[63] 
Biomarker Reference Range 
R (min) 3.0–8.0 
K (min) 1.0–3.0 
MA (mm) 51.0–69 
  
 32 
Figure 1.6. TEG Tracing in Different Conditions
[71]† 
 
†
Modified from its original format 
1.7. PREVIOUS FACTOR VIII PHARMACOKINETIC AND PHARMACODYNAMIC 
ANALYSIS: 
1.7.1. Previous Factor VIII Pharmacokinetic Modeling: 
A PK model describes the resulting plasma level over time for a dug, and therefore 
different PK parameters can be established.
[75]
 FVIII cannot be quantified by physiochemical 
assays due to its complex structure and function.
[55]
 Therefore, it is quantified in clinical settings 
by bioassays utilizing its coagulant activity (FVIII:C).
[47,55]
 FVIII PK models can be established 
by non-compartmental analysis (NCA) as well as by compartmental analysis (CA).
[46]
 FVIII 
NCA, also known as model-independent or free analysis, does not deal with FVIII PD 
response.
[46]
 It is also less influenced by best-fitting procedures (tedious processes subjected to 
errors).
[46]
 Therefore, it is popular among agencies concerned with FVIII bioequivalence.
[46]
 It 
can also be used as a reference for FVIII CA. FVIII CA deals with FVIII PD response.
[46]
 
Therefore, it is common among clinical PK studies.
[46]
 However, it is influenced by best-fitting 
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procedures that are subjected to errors (based on the blood sampling schedule and FVIII assay 
sensitivity/specificity).
[46,76]
 
FVIII CA includes the one-compartment body model as well as the two-compartment 
body model.
[76]
 The choice of FVIII CA depends on the terminal β phase (disposition part) of the 
plasma FVIII:C-time profile.
[76]
 The one-compartment body model is used upon observing a 
monophase in the terminal β phase, which indicates distribution of FVIII in only one 
compartment (Figure 1.7).
[76]
 The two-compartment body model is used upon observing a 
biphase in the terminal β phase, which indicates distribution of FVIII in two compartments 
(Figure 1.8).
[76]
 Obtaining a monophase or a biphase in the terminal β phase is influenced by the 
blood sampling schedule and FVIII assay sensitivity/specificity.
[46,76]
 A monophse in the terminal 
β phase has been observed by majority of FVIII CA studies, suggesting the one-compartment 
body model for FVIII replacement therapy.
[76]
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Figure 1.7. FVIII One-Compartment Body Model on a Logarithmic Scale
 
 
 
Figure 1.8. FVIII Two-Compartment Body Model on a Logarithmic Scale
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1.7.2. Previous Factor VIII Pharmacokinetic/Pharmacodynamic Modeling: 
A PK/PD model describes the resulting PD response over time for a drug and 
mathematically relates that PD response to the drug plasma level.
[75]
 Consequently, it allows 
establishment of different PD parameters. Current, as well as early, therapeutic drug monitoring 
(TDM) guidelines for FVIII replacement therapy relies heavily on FVIII PK models because 
hemophilia is actually FVIII deficiency, and its treatment revolves around replacing the deficient 
blood coagulation contributor, FVIII.
[77–82]
 Consequently, appropriate FVIII PK/PD models are 
lacking. FVIII PK models are developed in clinical settings by quantification of FVIII plasma 
levels using its plasma coagulant activity (plasma FVIII:C), which is quantified by appropriate 
bioassays (one-stage clotting, two-stage clotting or chromogenic substrate).
[47,52–55,57,58]
 All 
current FVIII bioassays include an appropriate PK/PD model to quantify plasma FVIII:C.
[47,52–
55,57,58]
 One-stage clotting assays include aPTT as a PD response.
[47,52–54,57,58]
 Two-stage clotting 
assays include fibrin formation time as a PD response.
[47,53,57,58]
 Chromogenic substrate assays 
include FXa ability to cleave a chromogenic substrate with a subsequent color absorbance as a 
PD response.
[47,53,57,58]
 All FVIII bioassays assume linearity in FVIII PD response over time 
(Figures 1.9 and 1.10).
[53,57]
 Therefore, FVIII PK/PD models are centered on the linear model.  
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Figure 1.9. FVIII PK/PD Linear Model Time Dependent Profile
 
 
 
Figure 1.10. FVIII PK/PD Linear Model Plasma FVIII:C Dependent Profile
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CHAPTER 2. THEORETICAL AND CONCEPTUAL APPROACH 
2.1. LITERATURE REVIEW: 
2.1.1. Factor VIII Prophylaxis: 
Among FVIII replacement therapy strategies, FVIII prophylaxis is becoming an accepted 
practice to reduce the prevalence of bleeding in severe hemophilia.
[83]
 The current clinical 
practice of FVIII prophylaxis revolves around converting patients with severe hemophilia 
phenotype (defined as plasma FVIII:C <1 IU dL
-1
) to moderate hemophilia phenotype (defined 
as plasma FVIII:C from 1–5 IU dL-1).[18,78–84] Such a procedure is hypothesized to reduce 
bleeding episodes in severe hemophiliacs, and subsequently preventing unfavorable outcomes, 
e.g., joint deterioration and muscle impairment.
[18,78–84]
 Therefore, FVIII prophylaxis in severe 
hemophilia remains controversial.
[85–87]
 However, several public health organizations and 
societies, e.g., World Health Organization (WHO), the World Federation of Hemophilia (WFH) 
and the Medical and Scientific Advisory Council (MASAC) of the United States National 
Hemophilia Foundation, consider its use in severe hemophiliacs with frequent bleeding episodes 
as a standard care.
[88]
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2.1.2. Bleeding Variability in Hemophilia A: 
A wide inter-individual variation in bleeding tendency, either frequent or infrequent, is 
observed in hemophilia (Table 2.1).
[89–93]
 Within this paradigm, many hemophiliacs with trough 
plasma FVIII:C ≥1 IU dL-1 (moderate or mild hemophilia phenotype) may experience a frequent 
breakthrough bleeding.
[89–91]
 Conversely, several hemophiliacs with plasma FVIII:C <1 IU dL
-1
 
(severe hemophilia phenotype) may exhibit an infrequent bleeding.
[89,92,93]
 Therefore, simply 
monitoring plasma FVIII:C in hemophiliacs to make clinical decisions regarding bleeding risk is 
flawed. A potential explanation is that current TDM standards, including plasma FVIII:C and 
aPTT, are measured within the plasma matrix, which reflects the classic model of blood 
coagulation (the cascade model [a sequential activation of various blood coagulation contributors 
in a dependent way]).
[48–54]
 Plasma FVIII:C and aPTT demonstrate neither the dynamic role of 
platelets nor the blood viscoelastic changes in hemophilia. Therefore, monitoring the hemostatic 
process in hemophilia using global hemostasis (platelet function and blood viscoelastic) 
biomarkers within the whole blood matrix may be more beneficial, especially that they reflect 
the modern model of blood coagulation (the cell-based model [an interdependent interaction 
between various blood coagulation contributors]).
[48–51,59,60]
 Global hemostasis biomarkers 
introduce the role of platelets and the blood viscoelastic changes in hemophilia.
[59,60]
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Table 2.1. Representative Studies Showing Bleeding Variability in Hemophilia 
Study Year Design n Key Results 
Ahnström et al.
[89] 
2004 Retrospective cohort with 
prospective PK analysis 
51 • Frequent joint bleeding 
with plasma FVIII:C ≥1 
IU dL
-1
 
• Infrequent joint bleeding 
with plasma FVIII:C <1 
IU dL
-1
 
van den Berg et al.
[90] 
2002 Retrospective cohort 70 • No change in joint 
bleeding with plasma 
FVIII:C ≥1 IU dL-1 
Carlsson et al
[91] 
1997 Randomized crossover 
PK analysis 
21 • Frequent joint bleeding 
with plasma FVIII:C ≥1 
IU dL
-1
 
Petrini
[92] 
2001 Retrospective cohort 43 • Infrequent joint bleeding 
despite plasma FVIII:C 
Ghosh et al.
[93] 
2001 Case-series  11 • Mild clinical presentations 
with plasma FVIII:C <1 
IU dL
-1
 
2.2. FACTOR VIII PHARMACOKINETIC/PHARMACODYNAMIC MODELING 
RATIONALE: 
In general, the corresponding plasma levels to dosing regimens of different drugs are best 
interpreted in the context of their biological responses.
[94]
 Therefore, considering their PK and 
PD aspects is a scientific approach used to modify, optimize and individualize their dosing 
regimens.
[94]
 In severe hemophilia, this scientific approach is applicable (Figure 2.1). An infusion 
of a FVIII prophylactic dose causes changes in plasma FVIII:C, i.e., PK changes, throughout its 
prophylactic interval. Subsequent changes in plasma FVIII:C exert responses on aPTT and 
global hemostasis (platelet function and blood viscoelastic) biomarkers, i.e., PD responses, 
throughout the FVIII prophylactic interval. The PK changes and the PD responses contribute to 
specific bleeding tendency, either frequent or infrequent. Therefore, relating the PK and PD 
aspects of FVIII prophylactic dosing by appropriate PK/PD modeling may allow assessment of 
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specific bleeding tendency in severe hemophilia. However, how plasma FVIII:C of FVIII 
prophylactic dosing relates to global hemostasis biomarkers in severe hemophilia represents a 
critical gap knowledge. Accordingly, appropriate PK/PD modeling using FVIII:C and global 
hemostasis biomarkers may enable to optimize and individualize FVIII prophylactic dosing for 
less breakthrough bleeding in severe hemophilia. 
Figure 2.1. FVIII PK/PD Modeling Rationale
 
 
2.3. ROLE OF MODIFIERS ON BLEEDING TENDENCY: 
Several factors may modify bleeding tendency in hemophilia (Figure 2.2). Fibrinogen 
and platelets are important blood coagulation contributors.
[48–51]
 Therefore, plasma fibrinogen 
content (measured in milligram per deciliter [mg L
-1
]) and platelet count (measured per liter [L
-
1
]) may modify specific bleeding tendency in hemophilia. Age, bodyweight and ethnicity are 
associated with multi-prothrombotic factors, e.g., pathophysiological changes, underlying 
diseases and gene expressions.
[95–97]
 In addition, age and bodyweight may influence FVIII PK 
characteristics.
[3,43]
 Therefore, age, bodyweight and ethnicity may modify specific bleeding 
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tendency in hemophilia. Different FVIII prophylactic regimens, e.g., two times per week or three 
times per week, may affect FVIII PK characteristics and its PD responses, and therefore specific 
bleeding tendency may be modified in hemophilia. Exploring clinically relevant modifiers of 
bleeding tendency may allow accurate assessment of specific bleeding tendency by appropriate 
PK/PD modeling for more optimal, individualized FVIII prophylactic dosing in severe 
hemophilia. 
Figure 2.2. Role of Modifiers on Bleeding Tendency in Hemophilia
 
 
2.4. OBJECTIVE AND CENTRAL HYPOTHESIS: 
The longstanding goal of this study was to establish optimal, individualized FVIII 
prophylactic dosing for less breakthrough bleeding in severe hemophilia. In order to accomplish 
this goal, we postulated employing global hemostasis (platelet function and blood viscoelastic) 
biomarkers, along with plasma FVIII:C, to optimize and individualize FVIII prophylactic dosing 
in severe hemophilia. Accordingly, the objective of this study, which was the initial stage toward 
accomplishing its longstanding goal, was to conduct appropriate PK/PD modeling using plasma 
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FVIII:C and global hemostasis (platelet function and blood viscoelastic) biomarkers in severe 
hemophilia. Therefore, the central hypothesis of this study was that following FVIII 
prophylactic dosing, specific bleeding tendency may be assessed by identifying how plasma 
FVIII:C corresponds to global hemostasis (platelet function and blood viscoelastic) biomarkers 
in an individual with severe hemophilia. 
2.5. SPECIFIC AIMS: 
The concepts and techniques in this study advanced the pharmacotherapy of hemophilia 
by challenging the current TDM standards for FVIII prophylaxis (plasma FVIII:C and aPTT) 
using novel global hemostasis (platelet function and blood viscoelastic) biomarkers. Briefly, the 
following specific aims (Figure 2.3) were conducted to achieve the objective of this study and 
evaluate its central hypothesis in severe hemophilia phenotype (plasma FVIII:C <1 IU dL
-1
) with 
different bleeding tendency (frequent versus infrequent): 
1.A. determine FVIII PK profiles over 48-h following FVIII prophylaxis dosing using 
plasma FVIII:C; 
1.B. determine FVIII PD profiles over 48-h following FVIII prophylaxis dosing using 
aPTT and global hemostasis biomarkers (platelet function [PCF, CEM and FOT] 
and blood viscoelasticity [R, K and MA]); 
1.C. explore clinically relevant modifiers of bleeding tendency, including plasma 
fibrinogen content, platelet count, age, bodyweight, ethnicity and FVIII 
prophylactic regimen; 
2. develop appropriate PK/PD models using FVIII PK and PD profiles determined 
over 48-h following FVIII prophylaxis dosing; and 
 43 
3. assess FVIII PK/PD models and clinically relevant modifiers of bleeding 
tendency quantitatively. 
Figure 2.3. Fitting the Specific Aims to the Study Rationale
 
 
2.6. SIGNIFICANCE: 
Patients with severe hemophilia are predisposed to recurrent bleeding episodes.
[18]
 Such 
bleeding episodes result in progressive joint deterioration and muscle impairment.
[18]
 These kind 
of disabilities subsequently lead to poor quality of life and economic burden due to extensive 
utilization of healthcare resources.
[11,18,98]
 The significance of this study is centered on its 
potential to provide a solid foundation for clinicians to assess bleeding tendency in severe 
hemophiliacs receiving FVIII prophylaxis using novel global hemostasis (platelet function and 
blood viscoelastic) biomarkers. For instance, instead of following plasma FVIII:C after 
prescribing a FVIII prophylactic dose and hoping to prevent bleeding episodes in patients with 
severe hemophilia, clinicians will have a chance to monitor more meaningful global hemostasis 
biomarkers throughout the FVIII prophylactic interval. Clinicians can then adjust FVIII 
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prophylactic dosing in more effective patient-specific need by observing normalized global 
hemostasis biomarkers throughout the FVIII prophylactic interval. Therefore, more optimal, 
individualized FVIII prophylactic dosing based on global hemostasis biomarkers in severe 
hemophilia may provide more cost-effective therapy by reducing bleeding episodes, 
hospitalizations and utilization of expensive FVIII products. Pilot data from this study will also 
provide a basis for future clinical trials of optimizing and individualizing FVIII prophylaxis in 
severe hemophilia. 
3.8. PRELIMINARY DATA: 
During a previous clinical study, we have obtained blood samples from patients with 
hemophilia at least 48 h following FVIII prophylaxis to asses plasma FVIII:C and the 
corresponding platelet function biomarkers, including PCF, CEM and FOT (Table 2.2).
[64]
 
Current dogma suggests that the concept of FVIII prophylaxis is to convert patients with severe 
hemophilia phenotype (defined as plasma FVIII:C <1 IU dL
-1
) to moderate hemophilia 
phenotype (defined as plasma FVIII:C from 1–5 IU dL-1).[18,78–84] However, we were able to 
show that there is a disconnect between simply following plasma FVIII:C and assuming 
protective hemostatic PD responses on platelet function. Although the patients marked with 
obelisk all have plasma FVIII:C ≥1 IU dL-1, they still have severely abnormal platelet function 
biomarkers (low PCF, low CEM and prolonged FOT). In fact, blood from the majority of these 
patients did not clot within 20 min, or at best it made a semi-formed liquid clot. This suggests 
that simply maintaining a trough plasma FVIII:C ≥1 IU dL-1 may not assure adequate platelet 
function. These data may also help explain the variability in bleeding tendency in patients with 
hemophilia who achieve a trough plasma FVIII:C ≥1 IU dL-1.  
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Table 2.2. Preliminary Data
[64] 
ID 
Plasma FVIII:C 
(IU dL
-1
) 
PCF 
(kdynes) 
CEM 
(kdynes cm
-2
) 
FOT 
(min) 
Patient 1 <1.0 0.40 0.00 ≥20 
Patient 2 <1.0 0.38 0.00 ≥20 
Patient 3 <1.0 0.22 0.00 ≥20 
Patient 4 <1.0 0.27 0.00 ≥20 
Patient 5 <1.0 0.37 0.00 ≥20 
Patient 6 <1.0 0.69 0.00 ≥20 
Patient 7
†
 5.0 0.80 0.00 ≥20 
Patient 8
†
 6.0 0.49 0.00 ≥20 
Patient 9
†
 4.0 0.56 0.00 ≥20 
Patient 10
†
 5.0 0.84 0.00 ≥20 
Patient 11
†
 6.0 2.47 5.91 15.0 
Patient 12
†
 14.0 2.10 6.46 15.0 
Patient 13
†
 1.0 0.44 0.00 ≥20 
Patient 14
†
 1.0 1.00 0.00 ≥20 
Patient 15 <1.0 0.60 0.00 ≥20 
Patient 16 <1.0 0.00 0.00 ≥20 
Patient 17
†
 1.0 0.41 0.00 ≥20 
Patient 18 <1.0 0.49 0.00 ≥20 
Patient 19
†
 4.0 1.45 6.39 15.0 
Patient 20
†
 1.0 0.44 0.00 ≥20 
Patient 21 <1.0 0.56 0.00 ≥20 
†Patients with a trough plasma FVIII:C ≥1 IU dL-1 
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CHAPTER 3. METHODS 
3.1. STUDY DESIGN: 
This was a prospective, open-label, single-dose, PK/PD pilot study. It established the 
PK/PD relationship of rFVIII prophylactic dosing using plasma FVIII:C (PK changes) and global 
hemostasis biomarkers (PD responses) over a 48-h prophylactic interval in severe hemophilia 
(plasma FVIII:C <1 IU dL
-1
). Global hemostasis biomarkers included PCF, CEM and FOT for 
assessment of platelet function and R, K and MA for assessment of blood viscoelasticity. This 
study also included aPTT as a PD response. This study assessed variability in bleeding tendency 
using appropriate PK/PD models. This study also explored the role of clinically relevant 
modifiers of bleeding tendency, including plasma fibrinogen content, platelet count, age, 
bodyweight, ethnicity and rFVIII prophylactic regimen. This study was awarded by the A.D. 
Williams Research Grant Committee. 
3.2. STUDY POPULATION: 
Prior to patient enrollment, the Virginia Commonwealth University (VCU) Institutional 
Review Board (IRB) approved this study. This study was conducted in compliance with the 
Declaration of Helsinki and the Health Insurance Portability and Accountability Act (HIPAA). 
Patients with eligibility criteria shown in Table 3.1 were identified at the Central Virginia Center 
for Coagulation Disorders (CVCCD), a registered HTC on the VCU Medical Center. Eligible 
patients were classified according to their historical bleeding tendency into two groups: frequent 
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and infrequent bleeders (Figure 3.1). Frequent bleeding tendency was defined as having >3 
bleeding episodes in major joints or muscles during the 6 months prior to study enrollment. 
Infrequent bleeding tendency was defined as having ≤3 bleeding episodes in major joints or 
muscles during the 6 months prior to study enrollment. This study was intended to enroll 10 
patients (5 patients per study group). Since this was a pilot study that aimed to acquire 
preliminary data to develop additional clinical trials with adequate power, the sample size (n = 
10) was based on the budgetary constraints of the A.D. Williams Grant. 
Table 3.1. Eligibility Criteria 
Inclusion Criteria Exclusion Criteria 
• Severe hemophilia (plasma FVIII:C <1 IU 
dL
-1
) 
• Prior FVIII dosing within 72 h of study 
procedures 
• Receiving rFVIII prophylaxis • FVIII inhibitory antibodies 
• ≥18 years of age • Active bleeding 
• Provision of written informed consent • Medical or family history of thrombosis 
 
Figure 3.1. Sample Size and Study Group Classification 
 
  
n = 10 
Eligible Patients 
n = 5 
Frequent Bleeders 
(>3 Bleeding Episodes in 6 Months) 
 
n = 5 
Infrequent Bleeders 
(≤3 Bleeding Episodes in 6 Months) 
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3.3. STUDY PROCEDURES AND DATA COLLECTION PLAN: 
3.3.1. Screening Visit: 
Screening visits were conducted in the CVCCD. Following the provision of written 
informed consent (Appendix 1), patients were screened for the eligibility criteria. Anonymous 
identification (ID) numbers were assigned to maintain confidentiality of patients. Demographics, 
FVIII deficiency information, rFVIII prophylaxis data, medical history (including bleeding 
tendency), family thrombotic history and concomitant medications were recorded in the 
screening visit form (Appendix 2). Patients received a physical examination to rule out active 
bleeding. A peripheral intravenous (IV) catheter was inserted for blood collection. Blood was 
collected in two Vacutainer 4.5-millimeters (mL) glass tubes containing 0.105 molar (M) 
trisodium citrate (BD, Franklin Lakes, NJ).  Blood samples were processed to determine 
different study variables (Table 3.2). All study documents were stored in a secure, locked filing 
cabinet after abstraction of their data in appropriate electronic files, which were maintained in a 
secure, password protected computer. 
3.3.2. Inpatient Visit: 
Eligible patients were admitted for inpatients visits in the VCU General Clinical Research 
Center (GCRC). Information of the inpatient visits were recorded in the inpatient visit form 
(Appendix 3). Patients received a brief physical examination to rule out active bleeding. A 
peripheral IV catheter was inserted for rFVIII prophylactic dose infusion and blood collection. 
Patients were infused with their routine rFVIII prophylactic dose over 5 min. Blood was 
collected at baseline and at 0.5-, 1-, 2-, 4-, 8- and 12-h post-rFVIII prophylactic dose infusion in 
two Vacutainer 4.5-mL glass tubes containing 0.105 M trisodium citrate (BD, Franklin Lakes, 
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NJ). Blood samples were processed to determine different study variables (Table 3.2). Chronic 
medications were allowed throughout the study. Patients received a physical examination before 
the discharge from their inpatient visits to rule out any potential risk. 
3.3.3. Outpatient Visit: 
Patients returned to the CVCCD for outpatient visits at 24-h post-rFVIII prophylactic 
dose infusion. Information of the outpatient visits were recorded in the outpatient visit form 
(Appendix 4). Patients received a brief physical examination to rule out active bleeding. A 
peripheral IV catheter was inserted for blood collection. Blood was collected in two Vacutainer 
4.5-mL glass tubes containing 0.105 M trisodium citrate (BD, Franklin Lakes, NJ). Blood 
samples were processed to determine different study variables (Table 3.2). Patients received a 
physical examination before the release from their outpatient visits to rule out any potential risk. 
Table 3.2. Blood Sampling Schedule 
Variable Screening 
Time Post-rFVIII Dose Infusion (h) 
0 ½ 1 2 4 8 12 24 48 
Plasma FVIII:C (IU dL
-1
) × × × × × × × × × × 
aPTT (sec) × × × × × × × × × × 
PCF (kdynes) × × × × × × × × × × 
CEM (kdynes cm
-2
) × × × × × × × × × × 
FOT (min) × × × × × × × × × × 
R (min) × × × × × × × × × × 
K (min) × × × × × × × × × × 
MA (mm) × × × × × × × × × × 
Plasma fibrinogen content (mg dL
-1
) ×          
Platelet count (L
-1
) ×          
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3.4. ANALYTICAL TECHNIQUES: 
Blood samples were processed for determination of the study variables using 
standardized analytical techniques as provided by the manufacturers (Table 3.3). Blood samples 
were processed in two laboratories. Plasma FVIII:C, aPTT, plasma fibrinogen content and 
platelet count were determined by the VCU Health System Department of Pathology Clinical 
Laboratory. Global hemostasis biomarkers (platelet function [PCF, CEM and FOT] and blood 
viscoelasticity [R, K and MA]) were determined in the Virginia Commonwealth University 
Coagulation Laboratory (VCAL). Plasma FVIII:C (based on one-stage clotting assay), aPTT and 
plasma fibrinogen content were measured using STart 4 (Diagnostica Stago Inc, Parsippany, NJ). 
Platelet count was measured using ADVIA 2120i (Siemens Healthcare Diagnostics Inc, 
Deerfield, IL). Platelet function biomarkers (PCF, CEM and FOT) were measured using HAS 
(Hemodyne Inc, Richmond, VA). Blood viscoelastic biomarkers (R, K and MA) were measured 
using TEG 5000 (Haemoscope Corp, Niles, IL). 
Table 3.3. Analytical Techniques 
Instrument Variable 
STart 4 (Diagnostica Stago Inc, Parsippany, NJ) • Plasma FVIII:C (IU dL-1) 
 • aPTT (sec) 
 • Plasma fibrinogen 
(mg dL
-1
) 
ADVIA 2120i (Siemens Healthcare Diagnostics Inc, Deerfield, IL) • Platelet count (L-1) 
HAS (Hemodyne Inc, Richmond, VA) • PCF (kdynes) 
 • CEM (kdynes cm-2) 
 • FOT (min) 
TEG 5000 (Haemoscope Corp, Niles, IL) • R (min) 
 • K (min) 
 • MA (mm) 
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3.5. PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS: 
3.5.1. Pharmacokinetic Modeling: 
Plasma FVIII:C-time profiles over 48-h following rFVIII prophylactic dosing were 
obtained for each patient. NCA was performed on each individual profile to estimate pertinent 
PK parameters.
[99]
 CA was performed after inspecting the terminal β phase (disposition part) of 
each individual profile using the following criteria: a monophasic decline trend as an indicator of 
the one-compartment body model; and a biphasic decline trend as an indicator of the two-
compartment body model.
[99]
 Accordingly, an appropriate CA model was fitted to plasma 
FVIII:C by non-linear regression. Pertinent PK parameters were estimated consequently. The 
choice of empiric weighing scheme, e.g., y
-1
, to correct for residual errors was made upon visual 
inspection of residuals. The goodness of fit was evaluated by coefficient of determination (r
2
) 
and model selection criterion (MSC). Estimated pertinent PK parameters along with associated 
standard deviation (SD) were evaluated as well. 
3.5.2. Pharmacokinetic/Pharmacodynamic Modeling: 
Following rFVIII prophylactic dosing, aPTT-time profiles over 48-h were obtained for 
each patient. In addition, global hemostasis biomarkers-time profiles over 48-h following rFVIII 
prophylactic dosing were obtained for each patient. Furthermore, aPTT-plasma FVIII:C profiles 
over 48-h following rFVIII prophylactic dosing were obtained for each patient. Moreover, global 
hemostasis biomarkers-plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing  
were obtained. Appropriate PK/PD modeling performed after inspecting each individual profile. 
Accordingly, plasma FVIII:C dependency on aPTT or global hemostasis biomarkers was fitted to 
an appropriate PK/PD model by non-linear regression. Pertinent PD parameters were estimated 
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consequently. The goodness of fit was evaluated by r
2
 and MSC. Estimated pertinent PD 
parameters along with associated standard deviation (SD) were evaluated as well. All necessary 
computerized PK and PK/PD modeling tasks were performed using Scientist Version 2.0 
(Micromath Research, Saint Louis, MO). 
3.6. STATISTICAL ANALYSIS: 
Appropriate descriptive statistics (mean [± SD], median [range] and count [%]) were 
used to characterize central tendency and dispersion. Correlation and analysis of variance 
(ANOVA), as appropriate, for pertinent PK and PD parameters were performed relative to 
clinically relevant modifiers of bleeding tendency (plasma fibrinogen content, platelet count, age, 
bodyweight, ethnicity and rFVIII prophylactic regimen) at baseline to assess possible source of 
PK and PD variability. Inter-group differences (frequent versus infrequent bleeders) in pertinent 
PK and PD parameters were assessed by ANOVA. P value <0.05 significance level was pre-
specified for all statistical tests. All statistical analyses were performed using JMP Version 9.0.2 
(SAS Institute Inc, Cary, NC).
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CHAPTER 4. RESULTS 
4.1. DEMOGRAPHICS: 
Over 16 months, approximately 10 hemophiliacs were screened each month. Of these 
hemophiliacs, 9 eligible hemophiliacs enrolled in this study. The demographics of these patients 
are presented in Tables 4.1 and 4.2. As shown in Figure 4.1, 5 patients (55.6%) exhibited 
frequent bleeding tendency while 4 patients exhibited infrequent bleeding tendency (44.4%). The 
mean (±SD) age was 41.7 (±15.9) years, and the median (range) age was 40 (20–62) years. The 
mean (±SD) bodyweight was 79.1 (±14.3) kilograms (kg), and the median (range) bodyweight 
was 81 (61–107) kg. The majority of patients were Caucasians (6 [66.7%]) while the others were 
African Americans (2 [22.2%]) and Asian (1 [11.1%]). One patient (11.1%) had HBV. Seven 
patients (77.8%) had HCV. Five patients (55.6%) had HIV. 
Table 4.1. Demographics 
ID 
Bleeding 
Tendency 
Age 
(Year) 
Bodyweight 
(kg) Ethnicity 
Comorbidity 
HBV HCV HIV 
Patient 1 Infrequent 62 107 African American No Yes Yes 
Patient 2 Infrequent 59 72 Caucasian No Yes No 
Patient 3 Infrequent 33 69 Asian No Yes Yes 
Patient 4 Frequent 46 83 Caucasian No Yes Yes 
Patient 5 Frequent 20 64 Caucasian No No No 
Patient 6 Frequent 60 61 Caucasian No Yes Yes 
Patient 7 Frequent 27 81 Caucasian No No No 
Patient 8 Frequent 28 86 Caucasian No Yes No 
Patient 9 Infrequent 40 88 African American Yes Yes Yes 
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Table 4.2. Demographics Summary 
Variable Mean (±SD) Median (Range) Count (%) 
Bleeding tendency       
Frequent     5 (55.6) 
Infrequent     4 (44.4) 
Age (year) 41.7 (±15.9) 40 (20–62)   
Bodyweight (kg) 79.1 (±14.3) 81 (61–107)   
Ethnicity       
African 
American   
  
2 (22.2) 
Asian     1 (11.1) 
Caucasian     6 (66.7) 
Comorbidity       
HBV     1 (11.1) 
HCV     7 (77.8) 
HIV     5 (55.6) 
 
Figure 4.1. Study Group Enrollment 
 
4.2. RECOMBINANT FACTOR VIII PROPHYLAXIS: 
Patients’ rFVIII prophylaxis data are presented in Tables 4.3 and 4.4. The mean (±SD) 
rFVIII prophylactic dose was 2,544.8 (±955.0) IU, and the median (range) dose was 2,300.0 
(1,560.0–4,464.0) IU. The mean (±SD) rFVIII prophylactic equivalent dose was 32.1 (±10.6) IU 
kg
-1
, and the median (range) equivalent dose was 28.7 (21.4–54.4) IU kg-1. Seven patients 
(77.8%) were on rFVIII prophylaxis two times per week while the other two patients (22.2%) 
n = 9 
Eligible Patients 
n = 5 
Frequent Bleeders 
(>3 Bleeding Episodes in 6 Months) 
 
n = 4 
Infrequent Bleeders 
(≤3 Bleeding Episodes in 6 Months) 
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were on rFVIII prophylaxis three times per week. The majority of patients were on Kogenate FS 
(4 [44.4%]) while the others were on Advate (1 [11.1%], Helixate FS (2 [22.2%]) and 
Recombinate (2 [22.2%]). 
Table 4.3. rFVIII Prophylaxis Data 
ID 
Dose 
(IU) 
Equivalent Dose 
(IU kg
-1
) 
Regimen 
(Times per Week) Product 
Patient 1 2,300.0 21.4 Two Kogenate FS 
Patient 2 2,058.0 28.7 Three Kogenate FS 
Patient 3 1,628.0 23.4 Three Helixate FS 
Patient 4 1,973.0 24.4 Two Advate 
Patient 5 2,400.0 36.3 Two Helixate FS 
Patient 6 1,560.0 25.6 Two Recombinate 
Patient 7 4,464.0 54.4 Two Kogenate FS 
Patient 8 3,520.0 40.9 Two Recombinate 
Patient 9 3,000.0 34.1 Two Kogenate FS 
 
Table 4.4. rFVIII Prophylaxis Data Summary 
Variable Mean (±SD) Median (Range) Count (%) 
Dose (IU) 2,544.8 (±955.0) 2,300.0 (1,560.0–4,464.0)   
Equivalent dose (IU kg
-1
) 32.1 (±10.6) 28.7 (21.4–54.4)   
Regimen (times per week)       
Two     7 (77.8) 
Three     2 (22.2) 
Product       
Advate     1 (11.1) 
Helixate FS     2 (22.2) 
Kogenate FS     4 (44.4) 
Recombinate     2 (22.2) 
4.3. PLASMA FIBRINOGEN CONTENT AND PLATELET COUNT: 
Plasma fibrinogen content and platelet count for the patients are presented in Tables 4.5 
and 4.6. The mean (±SD) plasma fibrinogen content was 334.9 (±52.4) mg dL
-1
, and the median 
(range) plasma fibrinogen content was 328.0 (264.0–441.0) mg dL-1. All patients had plasma 
fibrinogen content within the reference range (200.0–450.0 mg dL-1).[100] The mean (±SD) 
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platelet count was 260.4 (±70.2) x 10
9
 L
-1
, and the median (range) plasma fibrinogen content was 
261.0 (177.0–403.0) x 109 L-1. All patients had platelet count within the reference range (140.0–
440.0 x 10
9
 L
-1
).
[101]
 
Table 4.5. Plasma Fibrinogen Content and Platelet Count 
ID 
Plasma Fibrinogen 
(mg dL
-1
) 
Platelet Count 
(x10
9
 L
-1
) 
Patient 1 328.0 199.0 
Patient 2 264.0 261.0 
Patient 3 313.0 274.0 
Patient 4 289.0 273.0 
Patient 5 301.0 230.0 
Patient 6 441.0 323.0 
Patient 7 355.0 403.0 
Patient 8 367.0 177.0 
Patient 9 356.0 204.0 
 
Table 4.6. Plasma Fibrinogen Content and Platelet Count Summary 
Variable Mean (±SD) Median (Range) 
Plasma fibrinogen (mg dL
-1
) 334.9 (±52.4) 328.0 (264.0–441.0) 
Platelet count (x10
9
 L
-1
) 260.4 (±70.2) 261.0 (177.0–403.0) 
4.4. PHARMACOKINETIC MODELING: 
4.4.1. Non-Compartmental Analysis: 
Maximum concentration (Cmax), Vss, CLtot, t1/2, MRT and total area under the curve 
(AUC∞) of the plasma FVIII:C-time profile from standard NCA are presented in Tables 4.7 and 
4.8. The mean (±SD) Cmax was 88.0 (±31.5) IU dL
-1
, and the median (range) Cmax was 90.0 
(54.0–152.0) IU dL-1. The time to maximum concentration (tmax) was 30 min for all patients. The 
mean (±SD) Vss was 40.5 (±11.2) mL kg
-1
, and the median (range) Vss was 40.9 (22.8–58.2) mL 
kg
-1
. The mean (±SD) CLtot was 2.9 (±1.2) mL h
-1
 kg
-1
, and the median (range) CLtot was 3.0 
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(1.0–4.7) mL h-1 kg-1. The mean (±SD) t1/2 was 11.6 (±6.2) h, and the median (range) t1/2 was 7.6 
(6.8–23.8) h. The mean (±SD) MRT was 16.3 (±8.1) h, and the median (range) MRT was 12.3 
(8.7–33.8) h. The mean (±SD) AUC∞ was 738.2 (±260.0) international unit per milliliter per 
minute (IU mL
-1
 min
-1
), and the median (range) AUC∞ was 652.4 (472.7–1,325.5) IU mL
-1
 min
-1
. 
The extrapolated area under the curve from last point to infinity (AUCextra) of the plasma 
FVIII:C-time profile contributes to a small percentage of AUC∞. 
Table 4.7. NCA 
ID 
Cmax 
(IU dL
-1
) 
Vss 
(mL kg
-1
) 
CLtot 
(mL h
-1
 kg
-1
) 
t1/2 
(h) 
MRT 
(h) 
AUC∞ 
(IU mL
-1
 min
-1
) 
Patient 1 70.0 32.8 1.0 23.8 33.8 1,325.5 
Patient 2 68.0 35.5 3.0 7.3 11.9 576.9 
Patient 3 55.0 58.2 2.3 19.3 25.0 606.4 
Patient 4 116.0 22.8 1.5 12.0 15.4 964.8 
Patient 5 92.0 41.8 3.8 7.6 11.0 590.7 
Patient 6 54.0 55.8 3.2 13.4 17.3 472.7 
Patient 7 152.0 40.9 4.7 6.9 8.7 703.8 
Patient 8 90.0 43.0 3.8 7.4 11.4 652.4 
Patient 9 95.0 33.4 2.7 6.8 12.3 750.8 
 
Table 4.8. NCA Summary 
Parameter Mean (±SD) Median (Range) 
Cmax (IU dL
-1
) 88.0 (±31.5) 90.0 (54.0–152.0) 
Vss (mL kg
-1
) 40.5 (±11.2) 40.9 (22.8–58.2) 
CLtot (mL h
-1
 kg
-1
) 2.9 (±1.2) 3.0 (1.0–4.7) 
t1/2 (h) 11.6 (±6.2) 7.6 (6.8–23.8) 
MRT (h) 16.3 (±8.1) 12.3 (8.7–33.8) 
AUC∞ (IU mL
-1
 min
-1
) 738.2 (±260.0) 652.4 (472.7–1,325.5) 
4.4.2. Compartmental Analysis: 
Plasma FVIII:C-time profiles over 48-h following rFVIII prophylactic dosing (Figure 
4.2) showed a monoexponetial decline trend in the terminal β phase (disposition part). On a 
logarithmic scale (Figure 4.3), these profiles showed a monophasic decline trend in the terminal 
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β phase (disposition part), and therefore the one-compartment body model was selected. The 
one-compartment body model assumes instant and homogenous distribution of FVIII, and 
therefore plasma FVIII:C represents FVIII:C in all other tissues.
[99]
 Statistics and estimated PK 
parameters (Vss and CLtot) by fitting the one-compartment body model to plasma FVIII:C with 
-1y  empiric weighing scheme using non-linear regression are presented in Tables 4.9 and 4.10. 
The one-compartment body model showed a good fit as indicated by r
2
 (0.976–0.999). MSC 
(2.86–5.41) indicated a negligible to medium degree of over-parameterization. There was a very 
high precision in Vss and CLtot estimation as indicated by very low associated SD. The mean 
(±SD) Vss was 39.6 (±8.9) mL kg
-1
, and the median (range) Vss was 41.9 (21.0–51.3) mL kg
-1
. 
The mean (±SD) CLtot was 3.1 (±1.3) mL h
-1
 kg
-1
, and the median (range) CLtot was 3.0 (1.0–5.1) 
mL h
-1
 kg
-1
.  
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Figure 4.2. Plasma FVIII:C-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.3. Plasma FVIII:C-Time Profiles on a Logarithmic Scale
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Table 4.9. One-Compartment Body Model 
ID r
2
 MSC 
Vss (±SD)  CLtot (±SD) 
(mL kg
-1
)  (mL h
-1
 kg
-1
) 
Patient 1 0.995 5.41 31.8 (±1.1)  1.0 (±0.1) 
Patient 2 0.999 5.18 41.9 (±0.6)  3.0 (±0.1) 
Patient 3 0.976 3.61 44.9 (±3.4)  2.8 (±0.3) 
Patient 4 0.989 3.97 21.0 (±1.1)  1.6 (±0.1) 
Patient 5 0.994 5.24 42.6 (±1.6)  4.0 (±0.2) 
Patient 6 0.985 3.46 51.3 (±3.0)  3.6 (±0.3) 
Patient 7 0.994 4.39 36.4 (±1.5)  5.1 (±0.2) 
Patient 8 0.989 3.05 45.5 (±2.3)  4.1 (±0.3) 
Patient 9 0.991 2.86 40.8 (±1.9)  2.7 (±0.2) 
 
Table 4.10. One-Compartment Body Model Summary 
Parameter Mean (±SD) Median (Range) 
Vss (mL kg
-1
) 39.6 (±8.9) 41.9 (21.0–51.3) 
CLtot (mL h
-1
 kg
-1
) 3.1 (±1.3) 3.0 (1.0–5.1) 
4.5. PHARMACOKINETIC/PHARMACODYNAMIC MODELING: 
4.5.1. Activated Partial Thromboplastin Time: 
Following rFVIII prophylactic dosing, aPTT-time profiles over 48-h (Figure 4.4) showed 
changing aPTT over time, which is a critical prerequisite for PK/PD modeling of aPTT. In 
addition, aPTT-plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing (Figure 
4.5) exhibited a negative linear trend, i.e., as plasma FVIII:C increased, the corresponding aPTT 
decreased. (The unit of aPTT is sec [very small unit]; subsequently, aPTT-plasma FVIII:C 
profiles [Figure 4.5] exhibited a negative linear trend rather than a clockwise hysteresis loop 
[which may be appeared at the first glance].) Therefore, aPTT was PK/PD modeled using the 
linear model that assumes reduction in the PD response of a drug with increasing its plasma 
level, i.e., increasing plasma FVIII:C is parallel to the corresponding aPTT reduction in the 
biophase (site of action [the intrinsic pathway in the cascade model of blood coagulation]).
[75]
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Only two PD parameters were estimated using the linear model, and therefore the linear model 
was a good choice for aPTT in order to reduce the degree of over-parameterization. Statistics and 
estimated PD parameters (baseline effect [E0] and slope [a measure of aPTT sensitivity to 
changes in plasma FVIII:C]) by fitting plasma FVIII:C dependency on aPTT to the linear model 
using non-linear regression are presented in Tables 4.11 and 4.12. The linear model showed a 
good fit as indicated by r
2
 (0.941–0.998). MSC (0.40–2.23) indicated a medium to high degree of 
over-parameterization. There was a very high precision in E0 estimation as indicated by very low 
associated SD; however, there was a medium to high precision in slope estimation as indicated 
by low to medium associated SD. PK/PD linear modeling of aPTT showed reduction in the 
corresponding predicted aPTT with increasing the predicted plasma FVIII:C (Figures 4.6 and 
4.7). The mean (±SD) E0 was 48.9 (±4.4) sec, and the median (range) E0 was 49.5 (41.5–53.9) 
sec. The mean (±SD) slope was -0.025 (±0.009) second deciliter per international unit (sec dL 
IU
-1
), and the median (range) slope was -0.025 (-0.041– -0.013) sec dL IU-1.  
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Figure 4.4. aPTT-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.5. aPTT-Plasma FVIII:C Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
  
0
10
20
30
40
50
60
70
0 20 40 60 80 100 120 140 160
aP
T
T
 (
se
c)
 
Plasma FVIII:C (IU dL-1) 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Patient 6 Patient 7 Patient 8 Patient 9
 65 
Table 4.11. aPTT PK/PD Linear Model 
ID r
2
 MSC 
E0 (±SD)  Slope (±SD) 
(sec)  (sec dL IU
-1
) 
Patient 1 0.996 1.53 48.4 (±2.0)  -0.025 (±0.004) 
Patient 2 0.996 1.39 43.1 (±1.4)  -0.019 (±0.003) 
Patient 3 0.988 0.99 53.9 (±3.2)  -0.041 (±0.009) 
Patient 4 0.988 1.39 47.2 (±2.6)  -0.021 (±0.004) 
Patient 5 0.983 0.99 49.5 (±3.3)  -0.026 (±0.006) 
Patient 6 0.986 0.70 53.4 (±3.6)  -0.039 (±0.011) 
Patient 7 0.941 0.40 49.7 (±6.0)  -0.018 (±0.007) 
Patient 8 0.996 1.03 41.5 (±1.5)  -0.013 (±0.003) 
Patient 9 0.998 2.23 53.2 (±1.4)  -0.025 (±0.003) 
 
Table 4.12. aPTT PK/PD Linear Model Summary 
Parameter Mean (±SD) Median (Range) 
E0 (sec) 48.9 (±4.4) 49.5 (41.5–53.9) 
Slope (sec dL IU
-1
) -0.025 (±0.009) -0.025 (-0.041– -0.013) 
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Figure 4.6. aPTT PK/PD Linear Model Time Dependent Profile for Patient 9
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
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Figure 4.7. aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile for Patient 9
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
4.5.2. Platelet Contractile Force: 
PCF-time profiles over 48-h following rFVIII prophylactic dosing (Figure 4.8) showed 
changing PCF over time, which is a critical prerequisite for PK/PD modeling of PCF. In 
addition, PCF-plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing (Figure 
4.9) exhibited a positive linear trend, i.e., as plasma FVIII:C increased, the corresponding PCF 
increased as well. Therefore, PCF was PK/PD modeled using the linear model that assumes 
increasing the PD response of a drug with increasing its plasma level, i.e., increasing plasma 
FVIII:C is parallel to the corresponding PCF increase in the biophase (site of action 
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[platelet]).
[75]
 Statistics and estimated PD parameters (E0 and slope [a measure of PCF sensitivity 
to changes in plasma FVIII:C]) by fitting plasma FVIII:C dependency on PCF to the linear 
model using non-linear regression are presented in Tables 4.13 and 4.14. The linear model 
showed a good fit as indicated by r
2
 (0.879–0.976), except Patient 2 (r2 = 0.548). MSC (-0.43–
2.26) indicated a medium to very high degree of over-parameterization. There was a very low 
precision in E0 estimation as indicated by very high associated SD. Furthermore, there was a 
medium to high precision in slope estimation as indicated by medium to low associated SD, 
except Patient 2 (a very low precision in slope estimation as indicated by very high associated 
SD). PK/PD linear modeling of PCF showed increasing the corresponding predicted PCF with 
increasing the predicted plasma FVIII:C (Figures 4.10 and 4.11). The mean (±SD) E0 was 0.3 
(±0.3) kdynes, and the median (range) E0 was 0.3 (0.0–0.7) kdynes. The mean (±SD) slope was 
0.008 (±0.004) kilodynes deciliter per international unit (kdynes dL IU
-1
), and the median (range) 
slope was 0.009 (0.002–0.014) kdynes dL IU-1.  
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Figure 4.8. PCF-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.9. PCF-Plasma FVIII:C Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Table 4.13. PCF PK/PD Linear Model 
ID r
2
 MSC 
E0 (±SD)  Slope (±SD) 
(kdynes)  (kdynes dL IU
-1
) 
Patient 1 0.938 0.52 0.5 (±1.5)  0.013 (±0.003) 
Patient 2 0.548 -0.43 0.0 (±1.0)  0.002 (±0.002) 
Patient 3 0.908 0.67 0.6 (±0.9)  0.010 (±0.003) 
Patient 4 0.963 1.65 0.6 (±0.9)  0.009 (±0.001) 
Patient 5 0.956 1.15 0.7 (±0.5)  0.006 (±0.001) 
Patient 6 0.879 0.63 0.3 (±1.2)  0.014 (±0.004) 
Patient 7 0.976 2.26 0.0 (±0.5)  0.007 (±0.001) 
Patient 8 0.942 1.53 0.0 (±0.5)  0.005 (±0.001) 
Patient 9 0.971 1.92 0.0 (±0.6)  0.009 (±0.001) 
 
Table 4.14. PCF PK/PD Linear Model Summary 
Parameter Mean (±SD) Median (Range) 
E0 (kdynes) 0.3 (±0.3) 0.3 (0.0–0.7) 
Slope (kdynes dL IU
-1
) 0.008 (±0.004) 0.009 (0.002–0.014) 
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Figure 4.10. PCF PK/PD Linear Model Time Dependent Profile for Patient 7
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
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Figure 4.11. PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile for Patient 7
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
4.5.3. Clot Elastic Modulus: 
CEM-time profiles over 48-h following rFVIII prophylactic dosing (Figure 4.12) showed 
changing CEM over time, which is a critical prerequisite for PK/PD modeling of CEM. In 
addition, CEM-plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing (Figure 
4.13) exhibited a positive linear trend, i.e., as plasma FVIII:C increased, the corresponding CEM 
increased as well. Therefore, CEM was PK/PD modeled using the linear model that assumes 
increasing the PD response of a drug with increasing its plasma level, i.e., increasing plasma 
FVIII:C is parallel to the corresponding CEM increase in the biophase (site of action 
0
2
4
6
8
10
12
0 20 40 60 80 100 120 140 160
P
C
F
 (
k
d
y
n
es
) 
Plasma FVIII:C (IU dL-1) 
Observed (Plasma FVIII:C, PCF) Predicted (Plasma FVIII:C, PCF)
 74 
[platelet]).
[75]
 Statistics and estimated PD parameters (E0 and slope [a measure of CEM 
sensitivity to changes in plasma FVIII:C]) by fitting plasma FVIII:C dependency on CEM to the 
linear model using non-linear regression are presented in Tables 4.15 and 4.16. The linear model 
showed a good fit as indicated by r
2
 (0.868–0.969), except Patient 2 (r2 = 0.298). MSC (-0.49–
1.74) indicated a medium to very high degree of over-parameterization. There was a very low 
precision in E0 estimation as indicated by very high associated SD. Furthermore, there was a 
medium to high precision in slope estimation as indicated by low to medium associated SD, 
except Patient 2 (a very low precision in slope estimation as indicated by very high associated 
SD). PK/PD linear modeling of CEM showed increasing the corresponding predicted CEM with 
increasing the predicted plasma FVIII:C (Figures 4.14 and 4.15). The mean (±SD) E0 was 0.0 
(±0.0) kdynes cm
-2
, and the median (range) E0 was 0.0 (0.0–0.0) kdynes cm
-2
. The mean (±SD) 
slope was 0.032 (±0.016) kilodynes deciliter per international unit per square centimeter (kdynes 
dL IU
-1
 cm
-2
), and the median (range) slope was 0.027 (0.011–0.056) kdynes dL IU-1 cm-2.  
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Figure 4.12. CEM-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.13. CEM-Plasma FVIII:C Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Table 4.15. CEM PK/PD Linear Model 
ID r
2
 MSC 
E0 (±SD)  Slope (±SD) 
(kdynes cm
-2
)  (kdynes dL IU
-1
 cm
-2
) 
Patient 1 0.899 0.20 0.0 (±8.3)  0.056 (±0.017) 
Patient 2 0.298 -0.49 0.0 (±3.6)  0.011 (±0.008) 
Patient 3 0.902 0.55 0.0 (±3.9)  0.049 (±0.011) 
Patient 4 0.924 1.02 0.0 (±3.8)  0.027 (±0.005) 
Patient 5 0.908 0.59 0.0 (±2.2)  0.022 (±0.004) 
Patient 6 0.883 0.64 0.0 (±4.0)  0.048 (±0.013) 
Patient 7 0.949 1.39 0.0 (±2.1)  0.019 (±0.003) 
Patient 8 0.868 0.81 0.0 (±3.1)  0.018 (±0.006) 
Patient 9 0.969 1.74 0.0 (±2.3)  0.034 (±0.004) 
 
Table 4.16. CEM PK/PD Linear Model Summary 
Parameter Mean (±SD) Median (Range) 
E0 (kdynes cm
-2
) 0.0 (±0.0) 0.0 (0.0–0.0) 
Slope (kdynes dL IU
-1
 cm
-2
) 0.032 (±0.016) 0.027 (0.011–0.056) 
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Figure 4.14. CEM PK/PD Linear Model Time Dependent Profile for Patient 9
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
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Figure 4.15. CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile for Patient 9
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
4.5.4. Force Onset Time: 
FOT-time profiles over 48-h following rFVIII prophylactic dosing (Figure 4.16) showed 
changing FOT over time, which is a critical prerequisite for PK/PD modeling of FOT. In 
addition, FOT-plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing (Figure 
4.17) exhibited a clockwise hysteresis loop, i.e., as plasma FVIII:C increased, the reduction in 
FOT was delayed. Therefore, FOT was PK/PD modeled using the sigmoidal maximum effect 
(Emax) model that assumes a delay in the PD response of a drug with increasing its plasma level, 
i.e., increasing plasma FVIII:C corresponds to a delayed reduction in FOT in the biophase (site 
0
5
10
15
20
25
30
35
40
45
50
0 20 40 60 80 100 120 140 160
C
E
M
 (
k
d
y
n
es
 c
m
-2
) 
Plasma FVIII:C (IU dL-1) 
Observed (Plasma FVIII:C, CEM) Predicted (Plasma FVIII:C, CEM)
 80 
of action [platelet]).
[75]
 Statistics and estimated PD parameters (E0, Emax, half the maximum 
effective concentration [EC50] and Hill coefficient [n (a measure of FOT-plasma FVIII:C curve 
steepness)]) by fitting plasma FVIII:C dependency on FOT to the sigmoidal Emax model using 
non-linear regression are presented in Tables 4.17 and 4.18. The sigmoidal Emax model showed a 
good fit as indicated by r
2
 (0.947–0.995). MSC (-0.02–2.68) indicated a medium to very high 
degree of over-parameterization. There was a high precision in E0 estimation as indicated by low 
associated SD. There was a low precision in Emax estimation as indicated by high associated SD, 
except Patient 5 (a high precision in Emax as indicated by low associated SD). There was a very 
low precision in EC50 estimation as indicated by very high associated SD. The upper limit for the 
EC50 was set as the Cmax, which may have affected proper estimation of EC50. There was a very 
low precision in n estimation as indicated by very high associated SD. PK/PD sigmoidal Emax 
modeling of FOT showed a delayed reduction in the corresponding predicted FOT with 
increasing the predicted plasma FVIII:C (Figures 4.18 and 4.19). The mean (±SD) E0 was 19.8 
(±3.7) min, and the median (range) E0 was 21.0 (12.7–23.2) min. The mean (±SD) Emax was -
14.1 (±4.8) min, i.e., the mean (±SD) Emax was reduced by 70.1 (±16.9) %. The median (range) 
Emax was -14.3 (-20.7– -5.9) min, i.e., the median (range) Emax was reduced by 70.6 (41.9–98.4) 
%. The mean (±SD) EC50 was 87.8 (±31.4) IU dL
-1
, and the median (range) EC50 was 90.0 
(54.0–152.0) IU dL-1. The mean (±SD) n was 1.11 (±0.29), and the median (range) n was 1.10 
(0.59–1.46).  
 81 
Figure 4.16. FOT-Time Profiles
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†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.17. FOT-Plasma FVIII:C Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Table 4.17. FOT PK/PD Sigmoidal Emax Model 
ID r
2
 MSC 
E0 (±SD)  Emax (±SD) 
(min)  (min) 
Patient 1 0.959 0.60 20.9 (±2.9)  -16.0 (±21.6) 
Patient 2 0.974 -0.02 14.1 (±2.2)  -5.9 (±3.4) 
Patient 3 0.985 0.84 21.2 (±2.3)  -11.2 (±3.3) 
Patient 4 0.972 0.98 22.2 (±2.8)  -17.2 (±7.1) 
Patient 5 0.995 2.68 20.4 (±1.1)  -14.3 (±2.6) 
Patient 6 0.980 0.73 22.1 (±2.6)  -13.1 (±5.3) 
Patient 7 0.980 1.65 21.0 (±2.1)  -20.7 (±11.6) 
Patient 8 0.947 0.52 12.7 (±2.2)  -9.0 (±4.5) 
Patient 9 0.970 1.17 23.2 (±2.8)  -19.3 (±6.0) 
ID 
Emax 
(% Reduction) 
EC50 (±SD)  
n (±SD) (IU dL
-1
)  
Patient 1 76.6 70.0 (±103.5)  0.88 (±4.59) 
Patient 2 41.9 68.0 (±99.7)  1.43 (±2.28) 
Patient 3 52.8 55.0 (±41.6)  1.46 (±1.25) 
Patient 4 77.7 116.0 (±136.2)  0.92 (±0.79) 
Patient 5 69.8 90.0 (±34.5)  1.10 (±0.51) 
Patient 6 59.4 54.0 (±56.5)  1.13 (±1.09) 
Patient 7 98.4 152.0 (±304.9)  0.59 (±0.48) 
Patient 8 70.6 90.0 (±88.7)  1.36 (±2.23) 
Patient 9 83.4 95.0 (±76.3)  1.09 (±0.81) 
 
Table 4.18. FOT PK/PD Sigmoidal Emax Model Summary 
Parameter Mean (±SD) Median (Range) 
E0 (min) 19.8 (±3.7) 21.0 (12.7–23.2) 
Emax (min) -14.1 (±4.8) -14.3 (-20.7– -5.9) 
Emax (% Reduction) 70.1 (±16.9) 70.6 (41.9–98.4) 
EC50 (IU dL
-1
) 87.8 (±31.4) 90.0 (54.0–152.0) 
n 1.11 (±0.29) 1.10 (0.59–1.46) 
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Figure 4.18. FOT PK/PD Sigmoidal Emax Model Time Dependent Profile for Patient 5
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
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Figure 4.19. FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile for Patient 5
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
4.5.5. Reaction-Time: 
R-time profiles over 48-h following rFVIII prophylactic dosing (Figure 4.20) showed 
changing R over time, which is a critical prerequisite for PK/PD modeling of R. In addition, R-
plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing (Figure 4.21) exhibited 
a clockwise hysteresis loop, i.e., as plasma FVIII:C increased, the reduction in R was delayed. 
Therefore, R was PK/PD modeled using the sigmoidal Emax model that assumes a delay in the 
PD response of a drug with increasing its plasma level, i.e., increasing plasma FVIII:C 
corresponds to a delayed reduction in R in the biophase (site of action [clot]).
[75]
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estimated PD parameters (E0, Emax, EC50 and n [a measure of R-plasma FVIII:C curve 
steepness]) by fitting plasma FVIII:C dependency on R to the sigmoidal Emax model using non-
linear regression are presented in Tables 4.19 and 4.20. The sigmoidal Emax model showed a 
good fit as indicated by r
2
 (0.952–0.998). MSC (-0.13–4.21) indicated a negligible to very high 
degree of over-parameterization. There was a high precision in E0 estimation as indicated by low 
associated SD. There was a low precision in Emax estimation as indicated by high associated SD, 
except Patients 5 and 7 (a high precision in Emax as indicated by low associated SD). There was a 
very low precision in EC50 estimation as indicated by very high associated SD, except Patient 5 
(a medium precision in EC50 estimation as indicated by medium associated SD). The upper limit 
for the EC50 was set as the Cmax, which may have affected proper estimation of EC50. There was 
a very low precision in n estimation as indicated by very high associated SD, except Patient 5 (a 
medium precision in n estimation as indicated by medium associated SD). PK/PD sigmoidal Emax 
modeling of R showed a delayed reduction in the corresponding predicted R with increasing the 
predicted plasma FVIII:C (Figures 4.22 and 4.23). The mean (±SD) E0 was 23.9 (±8.4) min, and 
the median (range) E0 was 25.1 (12.1–37.1) min. The mean (±SD) Emax was -19.6 (±12.5) min, 
i.e., the mean (±SD) Emax was reduced by 74.9 (±26.0) %. The median (range) Emax was -20.4 (-
46.3– -3.7) min, i.e., the median (range) Emax was reduced by 78.9 (30.6–124.6) %. The mean 
(±SD) EC50 was 68.5 (±28.4) IU dL
-1
, and the median (range) EC50 was 68.0 (22.8–116.0) IU dL
-
1
. The mean (±SD) n was 1.20 (±0.58), and the median (range) n was 1.49 (0.31–1.85).  
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Figure 4.20. R-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.21. R-Plasma FVIII:C Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Table 4.19. R PK/PD Sigmoidal Emax Model 
ID r
2
 MSC 
E0 (±SD)  Emax (±SD) 
(min)  (min) 
Patient 1 0.960 0.99 24.8 (±3.0)  -20.4 (±16.5) 
Patient 2 0.984 -0.13 12.1 (±1.6)  -3.7 (±2.2) 
Patient 3 0.987 1.52 27.1 (±2.2)  -24.3 (±33.8) 
Patient 4 0.995 3.29 37.1 (±1.6)  -46.3 (±33.3) 
Patient 5 0.998 4.21 30.5 (±1.0)  -24.1 (±1.2) 
Patient 6 0.979 1.29 28.5 (±3.2)  -18.7 (±4.3) 
Patient 7 0.992 2.91 25.1 (±1.5)  -21.2 (±2.4) 
Patient 8 0.952 0.31 12.5 (±2.1)  -7.3 (±3.7) 
Patient 9 0.964 0.47 17.0 (±2.7)  -10.2 (±4.1) 
ID 
Emax 
(% Reduction) 
EC50 (±SD)  
n (±SD) (IU dL
-1
)  
Patient 1 82.1 70.0 (±83.8)  1.01 (±3.81) 
Patient 2 30.6 68.0 (±105.8)  1.62 (±2.94) 
Patient 3 89.9 55.0 (±378.3)  0.42 (±0.86) 
Patient 4 124.6 116.0 (±564.3)  0.31 (±0.27) 
Patient 5 78.9 45.5 (±8.4)  1.58 (±0.34) 
Patient 6 65.6 54.0 (±31.5)  1.85 (±1.43) 
Patient 7 84.5 22.8 (±11.4)  0.78 (±0.26) 
Patient 8 57.9 90.0 (±87.5)  1.73 (±4.22) 
Patient 9 59.8 95.0 (±93.0)  1.49 (±1.65) 
 
Table 4.20. R PK/PD Sigmoidal Emax Model Summary 
Parameter Mean (±SD) Median (Range) 
E0 (min) 23.9 (±8.4) 25.1 (12.1–37.1) 
Emax (min) -19.6 (±12.5) -20.4 (-46.3– -3.7) 
Emax (% Reduction) 74.9 (±26.0) 78.9 (30.6–124.6) 
EC50 (IU dL
-1
) 68.5 (±28.4) 68.0 (22.8–116.0) 
n 1.20 (±0.58) 1.49 (0.31–1.85) 
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Figure 4.22. R PK/PD Sigmoidal Emax Model Time Dependent Profile for Patient 5
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
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Figure 4.23. R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile for Patient 5
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
4.5.6. Kinetics-Time: 
K-time profiles over 48-h following rFVIII prophylactic dosing (Figure 4.24) showed 
changing K over time, which is a critical prerequisite for PK/PD modeling of K. In addition, K-
plasma FVIII:C profiles over 48-h following rFVIII prophylactic dosing (Figure 4.25) exhibited 
a clockwise hysteresis loop, i.e., as plasma FVIII:C increased, the reduction in K was delayed. 
Therefore, K was PK/PD modeled using the sigmoidal Emax model that assumes a delay in the 
PD response of a drug with increasing its plasma level, i.e., increasing plasma FVIII:C 
corresponds to a delayed reduction in K in the biophase (site of action [clot]).
[75]
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estimated PD parameters (E0, Emax, EC50 and n [a measure of K-plasma FVIII:C curve 
steepness]) by fitting plasma FVIII:C dependency on K to the sigmoidal Emax model using non-
linear regression are presented in Tables 4.21 and 4.22. The sigmoidal Emax model showed a 
good fit as indicated by r
2
 (0.956–0.999). MSC (-0.46–4.47) indicated a negligible to very high 
degree of over-parameterization. There was a high precision in E0 estimation as indicated by low 
associated SD. There was a very low to very high precision in Emax estimation as indicated by 
very low to very high associated SD. There was a very low precision in EC50 estimation as 
indicated by very high associated SD, except Patient 5 (a medium precision in EC50 estimation as 
indicated by medium associated SD). The upper limit for the EC50 was set as the Cmax, which 
may have affected proper estimation of EC50. There was a very low precision in n estimation as 
indicated by very high associated SD, except Patient 5 and 7 (a medium precision in n estimation 
as indicated by medium associated SD). PK/PD sigmoidal Emax modeling of K showed a delayed 
reduction in the corresponding predicted K with increasing the predicted plasma FVIII:C 
(Figures 4.26 and 4.27). The mean (±SD) E0 was 7.3 (±4.8) min, and the median (range) E0 was 
6.6 (3.0–18.6) min. The mean (±SD) Emax was 6.8 (±8.7) min, i.e., the mean (±SD) Emax was 
reduced by 73.2 (±36.4) %. The median (range) Emax was -4.9 (-29.2– -1.1) min, i.e., the median 
(range) Emax was reduced by 71.3 (29.8–157.2) %. The mean (±SD) EC50 was 67.2 (±29.0) IU 
dL
-1
, and the median (range) EC50 was 68.0 (31.4–116.0) IU dL
-1
. The mean (±SD) n was 1.41 
(±0.91), and the median (range) n was 1.83 (0.13–2.90).  
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Figure 4.24. K-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Figure 4.25. K-Plasma FVIII:C Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
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Table 4.21. K PK/PD Sigmoidal Emax Model 
ID r
2
 MSC 
E0 (±SD)  Emax (±SD) 
(min)  (min) 
Patient 1 0.956 0.50 6.6 (±1.0)  -4.9 (±5.9) 
Patient 2 0.968 -0.46 3.7 (±0.7)  -1.1 (±0.9) 
Patient 3 0.983 1.40 8.2 (±0.7)  -6.9 (±6.9) 
Patient 4 0.997 4.47 18.6 (±0.5)  -29.2 (±59.4) 
Patient 5 0.999 4.29 9.3 (±0.3)  -6.6 (±0.3) 
Patient 6 0.986 1.76 7.6 (±0.7)  -5.0 (±0.9) 
Patient 7 0.997 3.54 4.7 (±0.2)  -3.8 (±0.4) 
Patient 8 0.970 0.08 3.0 (±0.4)  -1.2 (±0.5) 
Patient 9 0.985 1.08 4.1 (±0.4)  -2.2 (±0.6) 
ID 
Emax 
(% Reduction) 
EC50 (±SD)  
n (±SD) (IU dL
-1
)  
Patient 1 74.0 70.0 (±105.8)  0.96 (±4.97) 
Patient 2 29.8 68.0 (±157.6)  2.09 (±6.38) 
Patient 3 84.2 31.4 (±128.3)  0.48 (±0.97) 
Patient 4 157.2 116.0 (±3,608.0)  0.13 (±0.29) 
Patient 5 71.3 48.7 (±9.9)  1.84 (±0.52) 
Patient 6 65.9 54.0 (±24.9)  1.86 (±1.14) 
Patient 7 81.2 31.7 (±15.0)  0.60 (±0.15) 
Patient 8 40.2 90.0 (±94.4)  2.90 (±17.99) 
Patient 9 55.0 95.0 (±59.0)  1.83 (±1.40) 
 
Table 4.22. K PK/PD Sigmoidal Emax Model Summary 
Parameter Mean (±SD) Median (Range) 
E0 (min) 7.3 (±4.8) 6.6 (3.0–18.6) 
Emax (min) -6.8 (±8.7) -4.9 (-29.2– -1.1) 
Emax (% Reduction) 73.2 (±36.4) 71.3 (29.8–157.2) 
EC50 (IU dL
-1
) 67.2 (±29.0) 68.0 (31.4–116.0) 
n 1.41 (±0.91) 1.83 (0.13–2.90) 
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Figure 4.26. K PK/PD Sigmoidal Emax Model Time Dependent Profile for Patient 5
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
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Figure 4.27. K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile for Patient 5
† 
 
†
Other individual profiles are presented in Appendices 5–13. 
4.5.7. Maximum Amplitude: 
MA-time profiles over 48-h following rFVIII prophylactic dosing (Figure 4.28) did not 
show changing in MA over time. MA values remained within the reference range throughout the 
rFVIII prophylactic dosing interval. Therefore, MA is considered a less sensitive blood 
viscoelastic biomarker. Changing in MA over rFVIII prophylactic dosing interval is a critical 
prerequisite for PK/PD modeling of MA. Therefore, MA was not PK/PD modeled.  
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Figure 4.28. MA-Time Profiles
† 
 
†
Individual profiles are presented in Appendices 5–13. 
4.6. CORRELATION AND INTER-GROUP DIFFERENCES: 
Clinically relevant modifiers of bleeding tendency (plasma fibrinogen content, platelet 
count, age, bodyweight, ethnicity and rFVIII prophylactic regimen) were assessed, and there 
were no significant associations/differences regarding pertinent PK and PD parameters. There 
was, however, a trend in age and CLtot from both NCA and CA. There were no significant inter-
group differences in pertinent PK and PD parameters between frequent and infrequent bleeders.
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CHAPTER 5. DISCUSSION 
5.1. PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS: 
To our knowledge, this was the first study that used different models to establish the 
PK/PD relationship of rFVIII prophylactic dosing using plasma FVIII:C and global hemostasis 
biomarkers (platelet function [PCF, CEM and FOT] and blood viscoelasticity [R, K and MA]) in 
whole blood over a 48-h prophylactic interval in 9 severe hemophiliacs (plasma FVIII:C <1 IU 
dL
-1
) with variant bleeding tendency. This study also included aPTT, the widely used platelet-
free biomarker in hemophilia. This study also explored the role of clinically relevant modifiers of 
bleeding tendency, including plasma fibrinogen content, platelet count, age, bodyweight, 
ethnicity and rFVIII prophylactic regimen. 
5.1.1. Pharmacokinetic Modeling: 
Pertinent PK parameters were estimated by both NCA and CA. NCA is an acceptable 
approach that provides reference PK parameters without the need to fit any data. Its accuracy and 
precision depend on AUC∞ estimation. AUC∞ estimation in this study was not an issue since 
AUCextra represented a small percentage of AUC∞, and therefore there was a confidence in the 
pertinent PK parameters (Vss, CLtot, t1/2 and MRT) estimated using NCA. In addition, the 
pertinent PK parameters (Vss, CLtot, t1/2 and MRT) estimated using NCA in this study (Table 4.8 
in Chapter 4) were consistent with those reported in representative single short infusion PK 
studies of FVIII in hemophilia (Table 1.10 in Chapter 1).
[ 3,35–40]
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CA is more challenging since it requires fitting the data using an appropriate PK model. 
CA was performed using the one-compartment body model after observing a monoexponetial 
and a monophasic decline trend in the terminal β phase (disposition part) of plasma FVIII:C-time 
profiles on the linear and the logarithmic scale, respectively, which indicated instant and 
homogenous distribution of FVIII throughout plasma and all other tissues, making the body 
behaved as a one-compartment for FVIII . The one-body compartment body model is a safe 
approach since it requires less intensive blood sampling schedule. Overall, there was a 
confidence in the pertinent PK parameters (Vss and CLtot) estimated using the one-compartment 
body model as indicated by the model statistics (r
2
 and MSC) and associated SD. In addition, the 
pertinent PK parameters (Vss and CLtot) estimated using the one-compartment body model (Table 
4.10 in Chapter 4) were consistent with those estimated using NCA (Table 4.8 in Chapter 4) and 
those reported in representative single short infusion PK studies of FVIII in hemophilia (Table 
1.10 in Chapter 1).
[ 3,35–40]
 
5.1.2. Pharmacokinetic/Pharmacodynamic Modeling: 
Changing a PD response (biomarker) over time following a drug administration is an 
important prerequisite for PK/PD modeling of that PD response. PD response-time profiles 
following rFVIII prophylactic dosing over 48-h indicated changing aPTT, PCF, CEM, FOT, R 
and K over time, but not MA. Therefore, aPTT, PCF, FOT, R and K were PK/PD modeled. MA 
(a measure of clot strength and stability) is considered to be a less sensitive blood viscoelastic 
biomarker because it remained within the reference range throughout the rFVIII prophylactic 
dosing interval. Changing aPTT over time following FVIII prophylactic dosing was consistent 
with the expected. Changing PCF, CEM and FOT, R, K and MA over time following FVIII 
prophylactic dosing have not been reported before. However, changing blood viscoelastic 
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biomarkers measured by Thromboelastometry (ROTEM), including clotting time (CT), clot 
formation time (CFT) and maximum clot firmness (MCF) over time following FVIII 
prophylactic dosing have been reported.
[102]
 In general, CT, CFT and MCF are equivalent to R, K 
and MA, respectively. Changing R, K and MA over time in this study were consistent with 
changing CT, CFT and MCF, respectively, over time following FVIII prophylactic dosing as 
previously reported.
[102]
 
Two PK/PD models were used: the linear and the sigmoidal Emax. The linear model was 
used for aPTT, PCF and CEM upon observing linear trend (negative for aPTT; positive for PCF 
and CEM) in PD response-plasma FVIII:C profiles. The linear model showed that increasing 
plasma FVIII:C was parallel to aPTT (a measure of the intrinsic pathway in the cascade model of 
blood coagulation) reduction, PCF (a measure of the force produced by platelets) increase and 
CEM (a measure of clot structural firmness) increase. The linear model has been used previously 
for aPTT to quantify FVIII replacement therapy (including its prophylaxis), especially within 
FVIII bioassays.
[53]
 The linear model has not been used previously for PCF and CEM to quantify 
FVIII replacement therapy (including its prophylaxis). Two pertinent PD parameters were 
estimated using the linear model: E0 and slope (PD response-plasma FVIII:C). Although the 
pertinent PD parameters (E0 and slope) estimated using the linear model for some patients were 
acceptable (as indicated by the model statistics [r
2
 and MSC] and associated SD), unacceptable 
estimation of the pertinent PD parameters (as indicated by the model statistics [r
2
 and MSC] and 
associated SD) can be optimized by more intensive blood sampling schedule over the rFVIIII 
prophylactic dosing interval. 
The sigmoidal Emax model was used for FOT, R and K upon observing a clockwise 
hysteresis loop in PD response-plasma FVIII:C profiles. The sigmoidal Emax model showed that 
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increasing plasma FVIII:C corresponded to a delayed reduction in FOT (a measure of clot 
initiation), R (a measure of clot initiation) and R (a measure of clot development). The sigmoidal 
Emax has not been used previously for FOT, R and K to quantify FVIII replacement therapy 
(including its prophylaxis). Four pertinent PD parameters were estimated using the sigmoidal 
Emax model: E0, Emax, EC50 and n. Although the pertinent PD parameters (E0, Emax, EC50 and n) 
estimated using the sigmoidal Emax model for some patients were acceptable (as indicated by the 
model statistics [r
2
 and MSC] and associated SD), unacceptable estimation of the pertinent PD 
parameters (as indicated by the model statistics [r
2
 and MSC] and associated SD) can be 
optimized by more intensive blood sampling schedule over a rFVIIII prophylactic dosing interval 
longer than 48-h. Over-parameterization was an issue in the PK/PD modeling using the 
sigmoidal Emax model since 4 pertinent PD parameters (E0, Emax, EC50 and n) were estimated. 
The upper limit for the EC50 was set as the Cmax in the PK/PD modeling, which may have 
affected proper estimation of EC50. Patients with high rFVIII prophylactic doses should be 
considered in future studies in order to maximize the chances of having Cmax more than EC50. 
5.2. PHARMACOKINETIC AND PHARMACODYNAMIC VARIABILITY: 
5.2.1. Pharmacokinetic Variability: 
There was inter-individual variation in plasma FVIII:C-time profiles over 48-h following 
rFVIII prophylactic dosing (Figures 4.2 and 4.3 in Chapter 4). It can be explained by variant 
degree of the pertinent PK parameters CLtot and t1/2. Plasma FVIII:C was used as a TDM 
standard to adjust the routine rFVIII prophylactic doses. Although the routine rFVIII 
prophylactic doses normalized plasma FVIII:C (≥1 IU dL-1) over the prophylactic interval 
(Figures 5.1 and 5.2), inter-individual variation in plasma FVIII:C failed to interpret variability 
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in bleeding tendency. For instance, low CLtot and long t1/2 were observed in both frequent 
(Patient 4) and infrequent (Patient 1) bleeders. High CLtot and short t1/2 were also observed in 
both frequent (Patient 7) and infrequent (Patient 2) bleeders. Plasma FVIII:C is measured within 
the plasma matrix, which does not reflect global hemostasis. 
Figure 5.1. Mean (±SD) Plasma FVIII:C-Time Profiles
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Figure 5.2. Mean (±SD) Plasma FVIII:C-Time Profiles on a Logarithmic Scale
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variation in aPTT. Measuring aPTT within the plasma matrix does not reflect global hemostasis, 
and aPTT, therefore, cannot explain viability in bleeding tendency. 
Figure 5.3. Mean (±SD) aPTT-Time Profiles
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contribute to variability in bleeding tendency. Although it was not true for all patients, there was 
a trend of having a higher PCF over 24-h following rFVIII prophylactic dosing in infrequent 
bleeders versus frequent bleeders.  PCF is measured within the whole blood matrix, and PCF, 
therefore, might better reflect global hemostasis. 
Figure 5.4. Mean (±SD) PCF-Time Profiles
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normalized throughout the prophylactic interval. The degree of inter-individual variation in CEM 
was higher than that of plasma FVIII:C. Consequently, inter-individual variation in CEM might 
contribute to variability in bleeding tendency. Although it was not true for all patients, there was 
a trend of having a higher CEM over 24-h following rFVIII prophylactic dosing in infrequent 
bleeders versus frequent bleeders.  CEM is measured within the whole blood matrix, and CEM, 
therefore, might better reflect global hemostasis. 
Figure 5.5. Mean (±SD) CEM-Time Profiles
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Force Onset Time. There was inter-individual variation in FOT-time profiles over 48-h 
following rFVIII prophylactic dosing (Figure 4.16 in Chapter 4). For most of the patients, FOT 
was sub-therapeutic by 8-h post-rFVIII prophylactic dosing (Figure 5.6). Therefore, FOT is more 
sensitive than PCF and CEM at lower plasma FVIII:C, and adjusting the routine rFVIII 
prophylactic doses by FOT, subsequently, might be more beneficial. The degree of inter-
individual variation in FOT was equivalent to that of plasma FVIII:C. In spite of that, variability 
in bleeding tendency might be interpreted by inter-individual variation in FOT since it was not 
normalized throughout the prophylactic interval. FOT is measured within the whole blood 
matrix, and FOT, therefore, might better reflect global hemostasis. 
Figure 5.6. Mean (±SD) FOT-Time Profiles
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Reaction-Time. There was inter-individual variation in R-time profiles over 48-h 
following rFVIII prophylactic dosing (Figure 4.20 in Chapter 4). For most of the patients, R was 
sub-therapeutic by 8-h post-rFVIII prophylactic dosing (Figure 5.7). Therefore, R is more 
sensitive than PCF and CEM at lower plasma FVIII:C, and adjusting the routine rFVIII 
prophylactic doses by R, subsequently, might be more beneficial. The degree of inter-individual 
variation in R was equivalent to that of plasma FVIII:C. In spite of that, variability in bleeding 
tendency might be interpreted by inter-individual variation in R since it was not normalized 
throughout the prophylactic interval. R is measured within the whole blood matrix, and R, 
therefore, might better reflect global hemostasis. 
Figure 5.7. Mean (±SD) R-Time Profiles
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Kinetics-Time. There was inter-individual variation in K-time profiles over 48-h 
following rFVIII prophylactic dosing (Figure 4.24 in Chapter 4). For most of the patients, K was 
sub-therapeutic by 24-h post-rFVIII prophylactic dosing (Figure 5.8). Therefore, adjusting the 
routine rFVIII prophylactic doses by K might be more useful since it was not normalized 
throughout the prophylactic interval. The degree of inter-individual variation in K was equivalent 
to that of plasma FVIII:C. In spite of that, variability in bleeding tendency might be interpreted 
by inter-individual variation in K since it was not normalized throughout the prophylactic 
interval. K is measured within the whole blood matrix, and K, therefore, might better reflect 
global hemostasis. 
Figure 5.8. Mean (±SD) K-Time Profiles
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Maximum Amplitude. There was inter-individual variation in MA-time profiles over 48-h 
following rFVIII prophylactic dosing (Figure 4.28 in Chapter 4). MA was therapeutic over the 
entire prophylactic dosing (Figure 5.9). Therefore, MA is the least sensitive biomarker that 
cannot be used to adjust the routine rFVIII prophylactic doses. It was not surprising since MA 
depends on plasma fibrinogen content, which was within the reference range.
[63]
 The degree of 
inter-individual variation in MA was less than that of plasma FVIII:C. Consequently, variability 
in bleeding tendency cannot be interpreted by inter-individual variation in MA. 
Figure 5.9. Mean (±SD) MA-Time Profiles
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5.3. LIMITATIONS: 
There are a few limitations in this study. First, the sample size was small. Having a small 
sample size did not allow demonstrating statistical significant differences between frequent and 
infrequent bleeders as well as the role of clinically relevant modifiers of bleeding tendency. For 
instance, there was a trend between age and CLtot (NCA and one-compartment body modeling) 
that did not reach the statistical significance. However, age was correlated with CLtot in other 
studies with a larger sample size.
[103]
 The small sample size of this study was a result of the 
budget limit as well as inadequate number of hemophiliacs that caused a slow patient 
recruitment. The slow patient recruitment was due to work related issues and low number of 
patients with severe hemophilia (plasma FVIII:C <1 IU dL
-1
) at the site of recruitment and 
screening. Second, this study established the PK/PD relationship of FVIII prophylaxis in non-
bleeding hemophiliacs, which was done given the larger characteristics from which to recruit. 
There is no logical reason to consider that the results may not be reproduced in hemophiliacs 
experiencing bleeding. Finally, this study did not assess the role of all clinically relevant 
modifiers of bleeding tendency. For instance, vWF plays an important role in FVIII CLtot, and 
bleeding tendency may be modified according to variant vWF plasma levels.
[3]
 In addition, 
coated-platelets are activated platelets that reinforce prothrombinase activity.
[104]
  Variation in 
percentage of coated-platelets was connected to variability in bleeding tendency.
[104]
 
Furthermore, protein C and protein S are important contributors of fibrinolysis.
[49]
 Variation in 
protein C and protein S plasma level, therefore, may contribute to variability in bleeding 
tendency.  
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5.4. CLINICAL IMPLICATIONS: 
There are currently no validated TDM standards for FVIII prophylaxis to assess its 
hemostatic PD response in severe hemophilia. Therefore, clinicians must depend on plasma 
FVIII:C and clinical symptoms of resolving bleeding. Based on non-validated TDM, FVIII 
prophylactic dose is altered, and clinicians hope that bleeding episodes will stop. Instead, TDM 
tests that assess the dynamic alterations in platelet function and blood viscoelasticity may be 
used. Consequently, assessing risk of bleeding and individualizing FVIII prophylactic dose in 
more patient-specific need by observing normalized platelet function (PCF, CEM and FOT) and 
blood viscoelasticity (R and K) may be more beneficial in severe hemophilia. 
5.5. CONCLUSIONS: 
This was a pilot study that established the PK/PD relationship of rFVIII prophylactic 
dosing using plasma FVIII:C and global hemostasis biomarkers (platelet function [PCF, CEM 
and FOT] and blood viscoelasticity [R, K and MA]) as well as aPTT over a 48-h prophylactic 
interval in severe hemophilia. Plasma FVIII:C was PK modeled by NCA and the one-
compartment body model. In addition, aPTT, PCF and CEM were PK/PD modeled by the linear 
model. Furthermore, FOT, R and K were PK/PD modeled by the sigmoidal Emax model. Plasma 
FVIII:C remained ≥1 IU dL-1 over the rFVIII prophylactic interval. Therefore, plasma FVIII:C 
was not a sensitive TDM standard. FOT and R, indicators of the speed of clot onset (which may 
relate more to the onset of bleeding in clinical settings), were more sensitive than PCF, CEM, K 
and aPTT since FOT and R were sub-therapeutic for a longer time at lower plasma FVIII:C 
following rFVIII prophylactic dosing. By applying the same concept, PCF and CEM were more 
sensitive than K and aPTT at lower plasma FVIII:C. MA was not PK/PD modeled because it 
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remained within the reference range following rFVIII prophylactic dosing. Therefore, MA was 
the least sensitive global hemostasis biomarker. Overall, PCF, CEM, FOT, R and K can be used 
to individualize FVIII prophylactic dose, monitor its hemostatic PD response and assess the risk 
of bleeding in severe hemophilia. However, future clinical trials should validate global 
hemostasis biomarkers in severe hemophilia using a larger sample size in order to demonstrate 
statistical significance and predict an effective FVIII prophylactic dose (and its frequency). Pilot 
data from this study can be used for power calculation. Multicenter clinical trials are encouraged 
in order to improve patient recruitment and archive the required sample size.
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Appendix 1. Written Informed Consent 
Protocol Title: “Therapeutic Drug Monitoring of Factor VIII Prophylaxis Using Its 
Plasma Coagulant Activity and Global Hemostasis Biomarkers: A 
Pharmacokinetic/Pharmacodynamic Pilot Study” 
Principle Investigator: Donald F. Brophy, PharmD, MS, FCCP, FASN, BCPS 
Sponsor: The A.D. Williams Research Program 
 This consent form may contain words that you do not understand. Please ask the study 
principle investigator or the study staff to explain any words or information that you do not 
clearly understand. You may take home an unsigned copy of this consent form to think about or 
discuss with family or friends before making your decision. 
Objective of the Study: 
Factor VIII (FVIII) is a drug that helps patients with hemophilia A, hereafter simply 
referred to as hemophilia, stop bleeding. However to date, there are currently no specific medical 
monitoring tests available to assess how well or how quickly it works in stopping bleeding. The 
objective of this study is to evaluate and determine the most appropriate medical monitoring tests 
for hemophiliacs who receive FVIII prophylaxis. You are being asked to enroll in this study 
because you have been diagnosed with hemophilia and may meet the study entry requirements.  
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Description of the Study: 
FVIII prophylaxis is used to reduce bleeding episodes in hemophiliacs. Your enrollment 
in this study will help clinicians better understand the effects of FVIII prophylaxis in 
hemophiliacs. All patients who meet eligibility criteria will have blood drawn after receiving 
their routine recombinant factor VIII (rFVIII) prophylactic dose. Blood samples will then be 
tested for the clotting ability of FVIII. Your participation in this study will last up to 
approximately two weeks, depending on your availability. Approximately 10 patients will 
participate in this study. Significant new findings developed during the course of the study that 
may relate to your willingness to continue enrollment will be provided to you. 
Procedures of the Study: 
If you decide to be in this research study, you will be asked to sign this consent form after 
you have had all your questions answered. Your first study visit (screening visit) will be in the 
Central Virginia Center for Coagulation Disorders (CVCCD), which is located at the Virginia 
Commonwealth University (VCU) Medical Center. At your screening visit, demographics, FVIII 
deficiency information, rFVIII prophylaxis data, medical history (including bleeding tendency), 
family thrombotic history and concomitant medications will be taken. You will also receive a 
physical examination. A peripheral intravenous (IV) catheter will be inserted into your arm vein 
for blood collection. Blood, approximately two teaspoons, will be collected. 
Your second study visit (inpatient visit) will take place within one week of your 
screening visit. At your inpatient visit, you will be admitted into the VCU General Clinical 
Research Center (GCRC) for 24 hours (h). Upon admission, you will receive a brief physical 
exam. A peripheral IV catheter will be inserted into your arm vein for rFVIII prophylactic dose 
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infusion and blood collection. You will be infused with your rFVIII prophylactic dose over 5 
minutes (min). Blood, approximately two teaspoons, will be collected at baseline and at 0.5-, 1-, 
2-, 4-, 8- and 12-h post-rFVIII prophylactic dose infusion. Before your discharge, you will 
receive a physical examination. 
Your last study visit (outpatient visit) will take place within 24 h of your inpatient visit. 
Your outpatient visit will be in the CVCCD. At your outpatient visit, you will receive a brief 
physical examination. A peripheral IV catheter will be inserted into your arm vein for blood 
collection. Blood, approximately two teaspoons, will be collected. Before your release, you will 
receive a physical examination. 
Risks and Discomforts: 
Risks and discomforts of this study are minimal and relate to the process of collecting 
blood from you. When inserting a peripheral IV catheter into your arm vein, you may feel a 
slight pain, like a bee sting. Other potential risks from peripheral venous blood collection include 
minor bleeding, bruising, irritation of the vein, clot in the vein, infection and passing out. Risks 
associated with rFVIII prophylactic dosing include development of clot. Other less severe risks 
include fever, headache, dizziness, injection site reactions, itching, rash, hematoma, mild muscle 
or joint pain, swelling in joints or muscles, chest pain or tightness, difficulty breathing, nausea, 
vomiting, hot flashes, chills and sweating. There may be risks or adverse drug events which are 
unknown at this time. There is the very unlikely risk of confidentiality breach. 
Benefits to You and Others: 
This is not a treatment study, and you are not expected to receive any direct medical 
benefits from your enrollment in the study. Information from this study may lead to development 
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of medical monitoring tests for the clotting ability of FVIII with the hope that this new medical 
monitoring tests will lead to better FVIII prophylaxis in the future for patients with hemophilia. 
Costs: 
There are no charges for the study visits. 
Payment for Enrollment: 
You will be paid for your enrollment in this study if you completed all the study visits. 
Alternatives: 
Your alternative is not to enroll in this study. 
Confidentiality: 
Potentially identifiable information about you will consist of data abstracted from your 
medical record. Data is being collected only for the study purpose. Your data will be identified 
by anonymous identification (ID) number and stored separately from medical records in a secure, 
locked filing cabinet. All personal identifying information in electron files will be kept in a 
secure, password protected computer. Access to all data will be limited to study personnel. You 
should know that the study data about you may be reviewed or copied by the sponsor of the 
study or by VCU. Although results of this study may be presented at meetings or in publications, 
identifiable personal information pertaining to patients will not be disclosed. 
Compensation for Injury: 
VCU and the VCU Health System have no plan for providing long-term care or 
compensation in the event that you suffer injury as a result of your enrollment in this study. If 
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you are injured or if you become ill as a result of your enrollment in this study, contact the study 
principle investigator or the study staff immediately. They will arrange for short-term emergency 
care or referral if it is needed. Fees for such treatment may be billed to you or to appropriate third 
party insurance. Your health insurance company may or may not pay for treatment of injuries as 
a result of your enrollment in this study. 
Voluntary Enrollment and Withdrawal: 
Your enrollment in this study is voluntary. You may decide to not enroll in this study. 
Your decision not to take part will involve no penalty or loss of benefits to which you are 
otherwise entitled. If you do enroll, you may freely withdraw from the study at any time. Your 
decision to withdraw will involve no penalty or loss of benefits to which you are otherwise 
entitled. Your enrollment in this study may be stopped at any time by the study principle 
investigator, the study staff or the sponsor of the study without your consent. The reasons might 
include: (i) it is necessary for your health or safety as might be decided by the study principle 
investigator or the study staff; (ii) you have not followed the study instructions; (iii) the sponsor 
of the study has stopped the study; or (iv) administrative reasons require your withdrawal. 
Questions: 
In the future, you may have questions about your study enrollment. You may also have 
questions about a possible adverse event to the study drug or a possible study-related injury. If 
you have any questions, complaints or concerns about the study, contact the study principle 
investigator or the VCU Office of Research. Do not sign this consent form unless you have had a 
chance to ask questions and have received satisfactory answers to all of your questions.  
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Donald F. Brophy (Principle Investigator) Office of Research 
VCU School of Pharmacy VCU 
Department of Pharmacotherapy and Outcomes Science 800 East Leigh Street, Suite 113 
410 North 12
th
 Street, Room 660 PO Box 980568 
PO Box 980533 Richmond, VA  23298 
Richmond, VA 23298 Phone: (804) 827-2157 
E-mail: dbrophy@vcu.edu 
Phone: (804) 827-1455 
Consent: 
I have been provided with an opportunity to read this written informed consent form 
carefully. All of the questions that I wish to raise concerning this study have been answered. By 
signing this written informed consent form, I have not waived any of the legal rights or benefits 
to which I would be otherwise entitled. My signature indicates that I freely consent to enroll in 
this study. I will receive a copy of the written informed consent form once I have agreed to 
enroll. 
_________________________________ 
 Patient’s Name (Printed) 
_________________________________ _________________________________ 
 Patient’s Signature Date (MM/DD/YYYY) 
_________________________________ 
 Name of Person Conducting 
 Written Informed Consent (Printed) 
_________________________________ _________________________________ 
 Signature of Person Conducting Date (MM/DD/YYYY) 
 Written Informed Consent 
_________________________________ _________________________________ 
 Principle Investigator’s Signature Date (MM/DD/YYYY)
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Appendix 2. Screening Visit Form 
Protocol Title: “Therapeutic Drug Monitoring of Factor VIII Prophylaxis Using Its Plasma 
Coagulant Activity and Global Hemostasis Biomarkers: A Pharmacokinetic 
/Pharmacodynamic Pilot Study” 
Date:  _______________ (MM/DD/YYYY) 
Patient’s Identification (ID) Number:  ________________ 
Age:  __________ (Years) 
Bodyweight: _________ (Kilogram [kg]) 
Ethnicity: □ African American □ American Indian or Alaska Native 
 □ Asian □ Caucasian 
 □ Hispanic □ Native Hawaiian or Other Pacific Islander 
Primary Diagnosis: Severe Factor VIII (FVIII) Deficiency 
Recombinant Factor VIII (rFVIII) Product (Primary Medication): 
 □ Advate □ Helixate FS □ Kogenate FS 
 □ Recombinate □ ReFacto □ Xyntha 
rFVIII Prophylactic Dose:  _________ (International Unit [IU]) 
rFVIII Prophylactic Equivalent Dose:  _________ (International Unit per Kilogram [IU kg
-1
]) 
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rFVIII Prophylactic Regimen: □ Two Times Weekly □ Three Times Weekly 
Bleeding Tendency in the Past 6 Months: □ >3 Bleeding Episodes □ ≤3 Bleeding Episodes 
Secondary Diagnosis: 
1.  ______________________________________ 2. ____________________________________ 
3.  ______________________________________ 4. ____________________________________ 
5.  ______________________________________ 6. ____________________________________ 
7.  ______________________________________ 8. ____________________________________ 
Secondary Medications: 
1.  ______________________________________ 2. ____________________________________ 
3.  ______________________________________ 4. ____________________________________ 
5.  ______________________________________ 6. ____________________________________ 
7.  ______________________________________ 8. ____________________________________ 
Data Collector’s Signature: ________________ Date:  _______________ (MM/DD/YYY)
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Appendix 3. Inpatient Visit Form 
Protocol Title: “Therapeutic Drug Monitoring of Factor VIII Prophylaxis Using Its Plasma 
Coagulant Activity and Global Hemostasis Biomarkers: A Pharmacokinetic 
/Pharmacodynamic Pilot Study” 
Date:  _______________ (MM/DD/YYYY) 
Patient’s Identification (ID) Number:  ________________ 
Bodyweight: _________ (Kilogram [kg]) 
Recombinant Factor VIII (rFVIII) Product: 
 □ Advate □ Helixate FS □ Kogenate FS 
 □ Recombinate □ ReFacto □ Xyntha 
rFVIII Product Expiration Date:  _______________ (MM/DD/YYYY) 
rFVIII Product Lot Number:  _______________  
rFVIII Prophylactic Dose:  _________ (International Unit [IU]) 
rFVIII Prophylactic Equivalent Dose:  _________ (International Unit per Kilogram [IU kg
-1
])  
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Relative Time 
(Hour [h]) 
Actual Time 
(h) Blood Sampling Tubes Comments 
0  2  
   Infuse rFVIII prophylactic dose 
0.5  2  
1  2  
2  2  
4  2  
8  2  
12  2  
24  2  
Nurse’s Signature:  _______________________ Date:  _______________ (MM/DD/YYY)
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Appendix 4. Outpatient Visit Form 
Protocol Title: “Therapeutic Drug Monitoring of Factor VIII Prophylaxis Using Its Plasma 
Coagulant Activity and Global Hemostasis Biomarkers: A Pharmacokinetic 
/Pharmacodynamic Pilot Study” 
Date:  _______________ (MM/DD/YYYY) 
Patient’s Identification (ID) Number:  ________________ 
Relative Time 
(Hour [h]) 
Actual Time 
(h) Blood Sampling Tubes Comments 
48
†
  2  
†
Post-recombinant Factor VIII (rFVIII) prophylactic dose infusion 
Nurse’s Signature:  _______________________ Date:  _______________ (MM/DD/YYY)
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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PCF-Plasma FVIII:C Profile 
 
 
PCF PK/PD Linear Model Time Dependent Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
 
  
0
5
10
15
20
25
0 20 40 60 80 100 120 140 160
F
O
T
 (
m
in
) 
Plasma FVIII:C (IU dL-1) 
0
5
10
15
20
25
0
20
40
60
80
100
120
140
160
0 5 10 15 20 25 30 35 40 45
F
O
T
 (
m
in
) 
P
la
sm
a 
F
V
II
I:
C
 (
IU
 d
L
-1
) 
Time (h) 
Observed Plasma FVIII:C Predicted Plasma FVIII:C
Observed FOT Predicted FOT
Appendix 5. Individual Profiles for Patient 1 
145 
FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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K-Plasma FVIII:C Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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PCF-Plasma FVIII:C Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
FOT-Time Profile 
 
  
0
5
10
15
20
25
30
35
40
45
50
0 20 40 60 80 100 120 140 160
C
E
M
 (
k
d
y
n
es
 c
m
-2
) 
Plasma FVIII:C (IU dL-1) 
Observed (Plasma FVIII:C, CEM)
Predicted (Plasma FVIII:C, CEM)
0
5
10
15
20
25
0 5 10 15 20 25 30 35 40 45
F
O
T
 (
m
in
) 
Time (h) 
Reference Range
Appendix 6. Individual Profiles for Patient 2 
158 
FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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PCF-Plasma FVIII:C Profile 
 
 
PCF PK/PD Linear Model Time Dependent Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
FOT-Time Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
 
 
aPTT-Time Profile 
 
  
1
10
100
0 5 10 15 20 25 30 35 40 45
L
o
g
(P
la
sm
a 
F
V
II
I:
C
 [
IU
 d
L
-1
])
 
Time (h) 
Reference Range
20
30
40
50
60
70
0 5 10 15 20 25 30 35 40 45
aP
T
T
 (
se
c)
 
Time (h) 
Reference Range
Appendix 8. Individual Profiles for Patient 4 
180 
aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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PCF-Plasma FVIII:C Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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PCF-Plasma FVIII:C Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
 
  
0
5
10
15
20
25
30
35
40
0 20 40 60 80 100 120 140 160
R
 (
m
in
) 
Plasma FVIII:C (IU dL-1) 
0
5
10
15
20
25
30
35
40
0
20
40
60
80
100
120
140
160
0 5 10 15 20 25 30 35 40 45
R
 (
m
in
) 
P
la
sm
a 
F
V
II
I:
C
 (
IU
 d
L
-1
) 
Time (h) 
Observed Plasma FVIII:C Predicted Plasma FVIII:C
Observed R Predicted R
Appendix 9. Individual Profiles for Patient 5 
203 
R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
MA-Time Profile 
 
0
2
4
6
8
10
12
14
16
18
20
0 20 40 60 80 100 120 140 160
K
 (
m
in
) 
Plasma FVIII:C (IU dL-1) 
Observed (Plasma FVIII:C, K)
Predicted (Plasma FVIII:C, K)
40
45
50
55
60
65
70
75
0 5 10 15 20 25 30 35 40 45
M
A
 (
m
m
) 
Time (h) 
Reference Range
 206 
Appendix 10. Individual Profiles for Patient 6 
Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
PCF-Time Profile 
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PCF-Plasma FVIII:C Profile 
 
 
PCF PK/PD Linear Model Time Dependent Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
CEM-Time Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
FOT-Time Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
R-Time Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
MA-Time Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
PCF-Time Profile 
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PCF-Plasma FVIII:C Profile 
 
 
PCF PK/PD Linear Model Time Dependent Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
CEM-Time Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
FOT-Time Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
R-Time Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
K-Time Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
MA-Time Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
PCF-Time Profile 
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PCF-Plasma FVIII:C Profile 
 
 
PCF PK/PD Linear Model Time Dependent Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
FOT-Time Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
K-Time Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
MA-Time Profile 
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Plasma FVIII:C-Time Profiles 
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Plasma FVIII:C-Time Profiles on a Logarithmic Scale 
 
 
aPTT-Time Profile 
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aPTT-Plasma FVIII:C Profile 
 
 
aPTT PK/PD Linear Model Time Dependent Profile 
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aPTT PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
PCF-Time Profile 
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PCF-Plasma FVIII:C Profile 
 
 
PCF PK/PD Linear Model Time Dependent Profile 
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PCF PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
CEM-Time Profile 
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CEM-Plasma FVIII:C Profile 
 
 
CEM PK/PD Linear Model Time Dependent Profile 
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CEM PK/PD Linear Model Plasma FVIII:C Dependent Profile 
 
 
FOT-Time Profile 
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FOT-Plasma FVIII:C Profile 
 
 
FOT PK/PD Sigmoidal Emax Model Time Dependent Profile 
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FOT PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
R-Time Profile 
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R-Plasma FVIII:C Profile 
 
 
R PK/PD Sigmoidal Emax Model Time Dependent Profile 
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R PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
K-Time Profile 
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K-Plasma FVIII:C Profile 
 
 
K PK/PD Sigmoidal Emax Model Time Dependent Profile 
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K PK/PD Sigmoidal Emax Model Plasma FVIII:C Dependent Profile 
 
 
MA-Time Profile 
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